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ABSTRACT 
 
 
 
INTRODUCTION: Cancer is one of the most common diseases in the developed world and 
both genetic and environmental factors play a role in the development of cancer. About 5-
10% of all cancers are due to predisposing genes. Some of the more common inherited cancer 
syndromes are hereditary breast and ovarian cancer (HBOC) and two colorectal cancer 
syndromes, familial adenomatous polyposis (FAP) and hereditary nonpolyposis colorectal 
cancer (HNPCC). Recognition of cancer susceptibility can allow “at risk” individuals and 
families to participate in cancer risk assessment, genetic testing, and various cancer 
prevention strategies. As the public is becoming more aware of inherited cancers, it is 
expected that there will be an increasing demand for genetic services and testing. For this 
reason more GP involvement is required to assess patients and families at risk and refer them 
appropriately. Since the Clinical and Counselling Section, Division of Human Genetics, 
National Health Laboratory Service and University of the Witwatersrand, Johannesburg is 
establishing a cancer genetics service it woud be of great value to assess the GPs‟ practice, 
knowledge and attitudes with regards to cancer genetics and this was therefore the aim of this 
study. 
 
METHODOLOGY: A quantitative, exploratory research design was chosen and GPs in the 
Johannesburg area were selected as subjects. After the completion of a pilot study a research 
package was mailed to 196 GPs. This package was sent out twice and both times the GPs 
were asked to respond within 3-4 weeks. The final sample consisted of 61 GPs and the data 
were analysed using descriptive statistics.  
 
RESULTS: Of the 61 participants more male GPs (42, 69%) than female GPs (19, 31%) 
responded and there were about an equal number of GPs practicing alone (29, 48) and in a 
multiple practice (32, 52%). Twenty two (33%) of the GPs had never had personal experience 
of cancer. Practices: The GPs made use of several cancer screening procedures but obtained 
limited information on cancer history from their patients particularly from second degree 
relatives and about age of onset. Very few subjects (15, 25%) reported that they assess 
patients‟ risk for inherited cancer susceptibility and only 22 (36%) reported that they refer 
patients to other facilities for risk assessment and genetic testing. Knowledge: Only 32 (52%) 
of the GPs were aware of genetic testing facilities and 54 (86%) reported never having 
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received advertising material to promote genetic testing for cancer susceptibility services. 
They also are not aware of genetic counselling facilities but do feel patients should have 
genetic counselling by a genetic counselor, clinical geneticist or oncologist before genetic 
testing. Even though genetic testing for inherited cancer susceptibility is only available at 
some academic institutions, mostly on a research basis, the GPs seem to be unaware of the 
availability of genetic testing in South Africa for colorectal cancer genes (8, 13% and 9, 15%) 
but 28 (46%) knew about breast cancer genes. They were not aware of the autosomal 
dominant inheritance of hereditary breast cancer and the percentage of individuals with breast 
cancer who carry the BRCA1/2 gene nor did they know the penetrance of HNPCC genes. 
Attitudes: The subjects‟ attitudes to genetic testing for inherited cancer susceptibility were 
positive although they reported that they were unaware of several general factors regarding 
cancer genetic testing. The GPs had limited knowledge about inherited cancers and do not 
take an active part in cancer genetic management. However, 53 (87%) of the GPs reported 
interest in learning about these services and expected to play a role in cancer genetics in the 
future.  
 
CONCLUSION: The findings of this study suggest that there is a need to educate GPs about 
the basic cancer genetic concepts so that they can identify patients at risk for an inherited 
cancer syndrome. They need to be informed about the genetic tests currently available for the 
inherited cancer syndromes, and about genetic counselling and testing facilities. 
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GLOSSARY 
 
The terms in the glossary are adapted from Dorland‟s Illustrated Medical Dictionary (2003). 
 
Autosomal dominant inheritance: The expression of a trait in the heterozygous state, which 
is located on an autosome. 
 
Colonoscopy: An examination in which the doctor looks at the colon through a flexible,  
lighted instrument called a colonoscope. 
 
DNA: The primary carrier of genetic information.  It is a macromolecule usually consisting 
of a polynucleotide chain, phosphate and deoxyribose sugar.   
 
Exon: The DNA base sequences of a gene that encode amino acids. Exons are interspersed 
with non-coding regions called introns. 
 
Gene: A sequence of DNA that codes for a particular protein. 
 
Mastectomy:  Excision of the breast. 
 
Microsatellite: A small run of tandem repeats of nucleotides (usually less than 0.1kb) of a 
simple DNA sequence, usually 1-4 base pairs in length. 
 
Mutation: Alterations in the DNA sequence or chromosome structure that may alter the 
function of a gene and may cause disease.  
 
Oncogene: A gene capable under certain conditions of causing the initial and continuing 
conversion of normal cells into cancer cells. 
 
Oophorectomy: The removal of an ovary or ovaries. 
 
Polyp: A mass of tissue that projects into the colon. 
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Prophylactic surgery: Surgery performed before a particular phenotype manifests itself in 
an individual. 
 
Salpingo-oophorectomy: (Salpingo) – surgical removal of a uterine tube and ovary. 
 
Sigmoidoscopy: A procedure in which the doctor looks inside the rectum and the lower part 
of the colon (sigmoid colon) through a lighted tube.  
 
Tumour: An abnormal mass of tissue that results from excessive cell division.  They may 
either be benign (not cancerous) or malignant (cancerous). 
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APC                              Adenomatous polyposis coli gene 
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BRCA1  Breast cancer susceptibility gene 1 
BRCA2   Breast cancer susceptibility gene 2 
BSE    Breast self examinations 
CA-125              Cancer antigen 125 
CANSA                        Cancer Registry of South Africa 
CBE  `  Clinical breast examinations 
CHRPE                        Congenital hypertrophy of the retinal pigment epithelium 
CRC    Colorectal cancer 
DA    Diploma in anaesthesia 
DCH    Diploma in child health 
DFM    Department of family medicine 
DNA    Deoxyribonucleic acid 
DTMH   Diploma in tropical medicine and hygiene  
FAP     Familial Adenomatous Polyposis 
FDR                             First degree relative  
FOBT    Fecal occult blood test 
GP                                General practitioner 
HBOC                           Hereditary breast and ovarian cancer 
HER2                           Human epidermal growth factor receptor 2 
HNPCC   Hereditary Nonpolyposis Colorectal Cancer 
HRT    Hormone replacement therapy 
hMLH1    human MutL homologue 1 
hMSH2   human MutS homologue 2 
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MMR                           Mismatch repair genes 
MSI    Microsatellite instability 
MYH                             Mut Y human homolog 
NCR    National Cancer Registry 
NHLS    National Health Laboratory Service 
NF    Neurofibromatosis 
OC     Ovarian cancer 
PARP    Poly (ADP-ribose) polymerase 
SA     South Africa 
SAIMR              South African Institute for Medical Research 
SDR    Second degree relative 
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TS    Tumour suppressor gene 
USA    United States of America 
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                                                                 CHAPTER 1 
                                 INTRODUCTION AND LITERATURE REVIEW 
This chapter provides a brief overview of cancer, and two hereditary cancer syndromes, 
namely hereditary breast and ovarian cancer (HBOC) and colorectal cancer (CRC). Genetic 
counselling, in particular, cancer counselling is discussed. An overview of previous research, 
regarding GPs‟ practices and their understanding of hereditary cancers is also presented.  
1. LITERATURE REVIEW 
1.1. CANCER 
Cancer is one of the most common diseases in the developed world. Approximately 1 in 3 
individuals will develop cancer in their lifetime (Futreal, Kasprzyk, Birney et al., 2001). In 
South Africa, the national cancer registry (NCR), which was established in 1986 by the South 
African Institute for Medical Research (SAIMR), now the National Health Laboratory 
Service (NHLS), keeps an updated registry of cancers diagnosed by all the pathology 
laboratories in South Africa. The latest available results reported a total of 59 592 and 59 908 
new histologically diagnosed cancer cases in 1998 and 1999 respectively (Mqoqi, Kellett, 
Sitas et al., 2004).  
Cancer develops from a multi-step process and both genetic and environmental factors play a 
role; therefore cancer can occur as a sporadic event, or can be due to predisposing genes 
which can be inherited. Identification of these genetic and environmental influences are 
central aims of cancer research.  
Cells function in response to various biochemical signals and are programmed to divide, 
differentiate into mature cells, and die by means of programmed cell death (apoptosis). 
Changes in the cell signalling pathways, that occur as a result of various genetic and 
environmental insults, affect normal cell function and could eventually lead to cancer 
development in various cells and tissues. Several genes in these cells are known to play a role 
in cancer development. These genes, contributing to cancer, are known as proto-oncogenes, 
tumour suppressor genes, and mismatch repair genes, and are discussed in more detail later in 
this chapter.  
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Environmental factors that play a role in cancer development include sunlight (ultra violet 
radiation), chronic electromagnetic field exposure, ionising radiation, parasites, viruses, 
cellular oxygen deficiency, pesticide and herbicide residues, dioxins, unhealthy diet and free 
radicals (Wogan, Hecht and Felton et al., 2004; Emdin, 2004; Miller, Keku, Satia et al., 2007; 
Rudel, Attfield, Schifano et al., 2007). 
Any individual is at risk for developing cancer during his/her lifetime. Ultimately all cancers 
are the result of genetic changes which damage or mutate deoxyribonucleic acid (DNA) 
(Futreal et al., 2001). When a mutation in an individual‟s genes occurs at a somatic level, 
cancer is “acquired”. These mutations are present in 90-95% of all cancers (Harper, 2004). 
The remaining 5-10% of cancers are due to mutations that occur in the germline, thereby 
predisposing an individual to develop cancer (Harper, 2004). This is important because these 
mutations in the germline can be passed on, and thus will not only have serious consequences 
for an individual but also for subsequent generations (Turnpenny and Ellard, 2005). These 
germline mutations can cause a range of hereditary cancer syndromes.   
1.1.1. Cancer genes  
Proto-oncogenes, tumour suppressor genes, and DNA repair genes are known to play a role in 
cancer development. Each of these groups of genes plays a role in the control of various cell 
regulation pathways and/or cell functions. Currently, it is estimated that about 1% of the total 
human genome is involved in cancer pathogenesis, and as cancer research progresses more 
genes are being identified. For example, currently there are 368 genes known which, if 
functioning abnormally, are involved in cancer pathogenesis, compared to the 291 reported in 
2004 (Futreal, Coin, Marchall, et al., 2004; Cancer Genome project, Jan 2008).  The majority 
of these genes are tumour supressor genes. Of the 291 genes involved in cancer pathogenesis 
described by Futreal et al (2004) about 80% show somatic mutations, 10% demonstrate 
germline mutations and 10% show a combination of both germline and somatic mutations. 
Proto-oncogenes are known to play a role in signal transduction, a complex stepwise 
signalling pathway that controls cell proliferation and differentiation through transporting 
messages to and from the cell membrane through the cytoplasm into the nucleus (Turnpenny 
and Ellard, 2005). Point mutations and chromosome translocations can cause a disruption of 
the normal cell function and lead to over-activity of the signalling pathways and over-
production of proteins and thus transform the proto-oncogene into an oncogene. By 2005, 
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approximately 100 oncogenes had been identified (Futreal et al., 2001; Turnpenny and Ellard, 
2005).  
Tumour suppressor genes are known as protective genes, regulators or inhibitors. These 
genes suppress and regulate cell growth and death, and control cell division by encoding 
various proteins. Mutations in these genes cause a loss of control of cell growth. Tumour 
suppressor genes act recessively at a cellular level and obey the Knudson‟s two hit hypothesis 
(Knudson, 1971). This theory suggests that genes on both of an individual‟s chromosomes 
need to be mutated to lead to cancer. If an individual inherits a mutated gene on one 
chromosome they will need another “hit” (mutation) in their second gene in order to develop 
cancer. Examples of these genes include BRCA1-, BRCA2- (causing breast and ovarian 
cancer) and APC-[causing familial adenomatous polyposis (FAP)]. 
DNA repair genes function mainly in correcting errors that have occurred when DNA 
replicates. If the DNA repair gene fails to repair the errors, mutations may accumulate in 
many genes, resulting in dysfunction and cancer development. Examples of DNA repair 
genes include the mismatch repair genes, hMLH1, hMSH2 and hMSH6, mutated in hereditary 
non polyposis colorectal cancer (HNPCC) and the MYH gene mutated in autosomal recessive 
FAP (Firth and Hurst, 2006). 
1.1.2. Diagnosis of hereditary cancers  
Many cancers show familial clustering, and seem to be due to inherited predisposing genetic 
factors (Lindor, Greene, Mayo et al., 1998). Some of these so-called cancer syndromes are 
Hereditary breast/ovarian cancer syndrome (HBOC), Hereditary non-polyposis colorectal 
cancer, familial adenomatous polyposis, Li-Fraumeni syndrome, Multiple endocrine 
neoplasia (MEN) syndrome types 1 and 2, Neurofibromatosis (NF) types 1 and 2, von 
Hippel-Lindau disease, Bloom syndrome and familial pancreatic cancer. For the purposes of 
this study, HBOC and colorectal cancer (CRC) syndromes will be discussed in detail.   
There are several diagnostic clues that can indicate if an individual or family is at risk for a 
hereditary cancer (Lynch, Lynch, Casey et al., 1997; Lindor et al., 1998; Harper, 2004; 
Lalloo, Kerr, Friedman et al., 2006). These include: 
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(1) Two or more first and/or second degree relatives with the same common cancer 
(2) Several first and/or second degree relatives who have a related type of cancer  
(3) Two members in the family with the same rare cancer  
(4) Two members in the family with related rare cancers 
(5) Early age of onset for the specific cancer type 
(6) Bilateral cancer  
(7) Multi-focal tumours  
(8) More than one type of associated cancer in one individual  
This information is essential to determine whether an individual or family is at risk of 
developing a hereditary cancer syndrome. Recognition of cancer susceptibility can allow “at 
risk” individuals and families to participate in cancer risk assessment, genetic testing, and 
various cancer prevention strategies like intensive surveillance, prophylactic surgery and 
cancer prevention therapy (Kausmeyer, Lengerich, Kluhsman et al., 2006). Diagnosis of a 
hereditary cancer syndrome usually depends on gathering detailed information about critical 
family members. Critical family members do not only include the affected individual, but 
also all the 1
st
 degree relatives (siblings, offspring and parents), second degree relatives 
(aunts, uncles and grandparents), and cousins. Cancer details such as the type of cancer, 
primary site of tumour, if metastasis occurred, bilateral tumours, the age of onset, and the 
cause and age of death are important to assess. Tumour histology should also be fully 
documented (Hoskins, Stopfer, Calzone et al., 1995). 
Risk assessment can divide individuals or families with a cancer history into three risk 
categories namely: average, moderate and high. Cancers in average risk families are not 
usually considered to be a result of a predisposing inherited cancer gene and these individuals 
should follow screening protocols as set for the general population. Moderate risk families 
have a family history of cancer and include some affected individuals; the age of onset is 
older and the cancer cause is usually multi-factorial. High risk families have a more striking 
family history including multiple affected members. They show a clear autosomal dominant 
(AD) inheritance pattern, and early age of cancer onset (Lalloo et al., 2006). The offspring of 
a mutation positive individual for an autosomal dominant hereditary cancer has a 1 in 2 or 
50% chance of inheriting the predisposition to cancer. For these high risk individuals genetic 
testing is offered (if available), and stricter surveillance procedures are available. Once an 
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individual is found to be a mutation carrier for a hereditary cancer syndrome they might 
consider the option of prophylactic surgery. 
1.2. SPORADIC AND HEREDITARY BREAST AND OVARIAN CANCER  
1.2.1. Sporadic breast and ovarian cancer 
Breast cancer (BRCA) and ovarian cancer (OC) are two of the most common cancers that 
occur in females. About 90-95% of these cancers are sporadic (Harper, 2004).  
1.2.1.1. Incidence  
According to the NCR, a total of 5901 new histologically diagnosed cases of BRCA were 
reported in 1998-1999 in SA, making this the commonest type of cancer amongst women. 
Over these two years about 1 in 27 females were estimated to be at risk of developing BRCA 
in their life time (Mqoqi et al., 2004). The lifetime risk is highest in white females, followed 
by coloured and Asian females sharing a similar incidence, and black females having the 
lowest incidence rate (Sitas, Madhoo, Wessie et al., 1998; Mqoqi et al., 2004)                    
(See Table 1.1).  
Ovarian cancer has been described as the seventh most common cancer among women and 
the lifetime risk of developing this cancer is 1/180 (Mqoqi et al., 2004). In SA it is estimated 
that the lifetime risk in the white population of developing ovarian cancer is higher than that 
of the black, coloured and Asian populations (See Table 1.1). No data on BRCA and OC 
occurring together in the SA population have been documented. 
Table 1.1: Lifetime risks for breast and ovarian cancer by population group in SA in 1999 
(Mqoqi, 2004).  
 Breast cancer LR¹ Ovarian cancer LR¹ 
White 
Black 
Coloured 
Asian 
1/12 
1/49 
1/18 
1/18 
              1/82 
1/313 
1/159 
1/121 
¹ LR: Lifetime risk suggesting that every 1 in X number of individuals will develop cancer between the ages of 0 and 
74 years. 
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1.2.1.2. Risk factors  
Every woman is at risk of developing breast and/or ovarian cancer in her lifetime. The 
majority of sporadic cases are reported in post-menopausal women (55 years and older) 
(Philips, Glendon and Knight, 1999; Norman, Bradshaw, Groenewald et al., 2006). Breast 
and ovarian cancer have a multifactorial aetiology and it is therefore suggested that 
reproductive, hormonal, environmental, as well as genetic factors play a role in cancer 
development. The risk factors that increase the risk of developing breast cancer are 
summarized in Table 1.2. 
Table 1.2: Factors increasing the risk of developing breast cancer (Adapted from Hsieh, 
Trichopoulos, Katsouyanni et al., 1990; Kelsey, Gammon, and John, 1993; Lipworth, 1995; 
Lim, Hearle, Shah et al., 2003; Reeves, Yawitch, van der Merwe et al., 2004; Brody et al., 
2007; Rudel et al., 2007). 
 Risk factors 
 
Reproductive factors 
 
 Early menstruation (before age 12)  
 Late menopause (after age 54) 
 Nulliparous woman  
 First child at a later age,  over age 30 years 
Hormonal factors 
 
 Combined oral contraceptive pill 
 Hormone replacement therapy (HRT) 
Environmental 
factors 
 
 Obesity 
 Alcohol consumption, and smoking 
 Exposure to estrogen-like chemicals in pesticides and 
other industrial products 
 Radiation 
Genetic factors 
 
 Breast cancer predisposing genes, BRCA1 and BRCA2 
genes 
 Strong family history of breast and/or ovarian cancer 
with AD inheritance pattern 
 High risk population groups such as Afrikaners and 
Ashkenazi Jewish  
 Presence of other rare cancer causing syndromes such as 
Fanconi anaemia, Peutz-Jeghers syndrome.  
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Pregnancy (before the age of 30 years), breast feeding, healthy diet and exercise are 
protective risk factors and therefore decrease the risk of developing breast cancer (Brody, 
Rudel, Michels, et al., 2007).  
1.2.1.3. Detection and management  
The Cancer Registry of South Africa‟s (CANSA) recommendations for healthy breast care 
include: monthly breast self examinations (BSE) for all women, thorough clinical breast 
examinations (CBE) done by a health professional every 1-2 years and mammography 
screening annually after the age of 50 years.  
Breast and ovarian cancer can be treated surgically and in addition treatments such as 
chemotherapy, radiation therapy and the use of chemoprevention drugs such as tamoxifen® 
are available. The type of treatment will be based on the site and stage of the cancer. There 
are various oncology centres across SA that manages cancer patients. 
1.2.2. HEREDITARY BREAST AND OVARIAN CANCER SYNDROME 
Lynch and Krush (1971) studied three families which included members with both breast and 
ovarian cancer, where they described hereditary breast-ovarian cancer syndrome (HBOC). 
Since then, research has focused on finding genetic as well as environmental factors for this 
hereditary cancer syndrome.  
Approximately 5-10% of all breast and/or ovarian cancer cases are caused by predisposing 
genetic factors, HBOC is inherited in an autosomal dominant manner with incomplete 
penetrance (Harper, 2004). Thus, if an individual carries an inherited mutated gene, he/she is 
predisposed to develop the cancer syndrome. However, with incomplete penetrance it does 
not necessarily mean they will develop cancer in their lifetime. Individuals at risk of carrying 
a cancer predisposing mutation can be identified by using basic cancer risk criteria and 
assessing their family history.  
The genes responsible for causing HBOC syndrome are two tumour suppressor genes, Breast 
cancer susceptibility gene 1 (BRCA1) and Breast cancer susceptibility gene 2 (BRCA2). 
These two genes were found to be responsible for about 84% of HBOCs (Easton, Bishop, 
Ford et al., 1993; Ford, Easton and Stratton, 1998). Both of these genes are large with many 
exons (Miki, Swensen, Shattuck-Eidens et al., 1994; Wooster, Bignell, Lancaster et al., 1995) 
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and mutations may occur at any site throughout these genes. Certain characteristics in tumour 
pathology and hormonal constitution can be used as clues to distinguish between BRCA1 and 
BRCA2 mutations (Hedenfalk, Duggan, Chen et al., 2001). 
1.2.2.1. Breast cancer susceptibility gene 1 (BRCA1) 
The BRCA1 gene was mapped to chromosome 17q21 in 1990 (Hall et al., 1990) and 
identified in 1994 (Miki et al., 1994) as a susceptibility gene for breast and ovarian cancer. 
The gene consists of 24 coding exons and encodes a 220-kd protein of 1863 amino acids and 
frameshift or nonsense mutations are mostly present (Minki et al., 1994; Deng, 2006). To 
date approximately 800 BRCA1 mutations have been identified of which most are unique to a 
family (Petrucelli, Daly, Culver et al., 2007).   
BRCA1 germline mutation carriers have an estimated 44 - 78% lifetime risk to age 70 years 
for developing breast cancer, and an 18 - 54% lifetime risk for developing ovarian cancer 
(Firth and Hurst, 2006). There is also a 48% risk of developing contralateral breast cancer by 
the age of 50 years, and 64% by the age of 70 years (Haites et al., 2002). Such individuals are 
also at further risk for developing pancreatic, colon, prostate, endometrial, and cervical 
cancer (Ford, Easton, Bishop et al., 1994; Firth and Hurst, 2006).  
Histologically, BRCA1 tumours were mostly found to be estrogen, progesterone and 
epidermal growth factor 2 (HER-2) receptor negative (Lakhani, van de Vijver, Jacquemier et 
al., 2002; Reis-Filho and Tutt, 2008).  
1.2.2.2. Breast cancer susceptibility gene 2 (BRCA2) 
The BRCA2 gene was mapped in 1995 to chromosome 13q12-q13 (Collins, McManus, 
Wooster et al., 1995). This gene consists of 27 exons and encodes a 380-kd protein consisting 
of 3418 amino acids (Wooster et al., 1995; Petrucelli, Daly, Culver et al., 2007). Similar to 
BRCA1, about 800 BRCA2 mutations have been identified and again only a small number of 
these mutations have been identified repeatedly in unrelated families (Petrucelli et al., 2007).   
Female carriers of a BRCA2 mutation have a 31 - 56% risk of developing breast cancer and a 
2.4 - 19% risk of developing ovarian cancer by 70 years of age. Male BRCA2 mutation 
carriers have an estimated risk of 6% by age 70 years of developing male breast cancer             
(Firth and Hurst, 2006). Individuals are also at risk for developing prostate and pancreatic 
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cancers (Hahn, Greenhalf and Ellis, 2003), gall bladder/bile duct, larynx, oesophagus, colon, 
stomach cancer and malignant melanomas (Easton, Steele, Fields et al., 1997; Firth and 
Hurst, 2006).  
Unlike BRCA1 related tumours, BRCA2 tumours seem to test positive for both hormone 
receptors (oestrogen and progesterone) (Loman, Johannson, Bendahl et al., 1998). 
1.2.2.3. Founder mutations  
A founder mutation can be described as a mutation that is commonly found in a specific 
population group as a result of having a common ancestor. A founder effect may arise when a 
population become isolated and inbred.  
Founder mutations for HBOC syndrome have been reported in German, Polish, 
Scandinavian, Icelandic, and the Finnish population groups (Haites et al, 2002). In the 
Ashkenazi Jewish population, three founder mutations have been identified- 185delAG and 
5382insC in the BRCA1 gene, and 6174delT in the BRCA2 gene (Streuwing, Abeliovich, 
Peretz et al., 1995; Streuwing, Hartge, Wacholder et al., 1997). Founder mutations have also 
been identified in the Afrikaner population. Five Afrikaner families were found to have an 
E881X mutation (Reeves, et al., 2004). To date, there are three mutations routinely tested for 
in Afrikaners namely E881X and 1493delC in the BRCA1 gene, and 8162delG in the BRCA2 
gene (van der Merwe and van Rensburg, 2007; van Rensburg, van der Merwe, Sluiter et al., 
2007). Van Rensburg et al (2007) determined that these unique Afrikaner mutations are found 
in 93% of HBOC families.  
1.2.2.4. Surveillance, treatment and management options for BRCA1/2 carriers 
Several prevention and detection strategies are available to BRCA1/2 carriers (see Table 1.3). 
Surveillance tests are used to identify and diagnose breast cancer and/or ovarian cancer early. 
Screening should commence at about 25-35 years of age or a few years before the earliest 
diagnosis of breast and/or ovarian cancer, or any other related cancer, in a family (Horsman, 
Wilson, Avard et al., 2007). Since BRCA1/2 carriers are also at risk of developing other 
cancers, the individual and medical professionals should be alerted.  
Prophylactic options include bilateral mastectomy and/or salpingo-oophorectomy (see 
glossary). Bilateral prophylactic mastectomy reduces the risk of developing breast cancer by 
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about 91%, and bilateral oophorectomy (see glossary) reduces breast cancer risk by 
approximately 50% and ovarian cancer risk by 80-95% (van Sprundel, Schmidt, Rookus et 
al., 2005; Domcheck and Rebbeck, 2007).   
Table 1.3: Proposed management strategies for female BRCA 1/2 mutation carriers (adapted 
from Fasouliotis and Schenker, 2000; Warner, Plewes, Hill, et al., 2004; Horsman et al., 
2007). 
Disease Surveillance options Prophylactic options 
Breast 
cancer 
Monthly breast self examinations from 
18 years of age 
Six monthly or yearly clinical breast 
examination* 
Annual Mammography scans* or 
Annual breast ultrasound scans* or 
Annual breast magnetic resonance 
imaging* 
Prophylactic mastectomy 
 
Chemoprevention drugs 
 
Oophorectomy 
Ovarian 
cancer 
Annual cancer antigen 125 (CA-125) 
screening* 
Annual ovarian ultrasound scans* 
Use of oral contraceptives 
Salpingo-oophorectomy 
* From about age 25-35 years 
Chemoprevention drugs such as Tamoxifen®, Raloxifen®, Aromatase® inhibition and 
Fenretinide® can be used as treatment or  prophylaxis for breast cancer and are known to 
reduce the incidence of further breast cancer (Newman and Vogel, 2007; Richardson, 
Johnston, and Pater et al., 2007). Another prophylactic method, which shows promise in 
actively playing a role in repairing DNA single-strand breaks, is Poly (ADP-ribose) 
polymerase (PARP). It is used as a therapeutic intervention as it targets the DNA repair 
defects in breast cancer mutant cells (Farmer, McCarbe, Lord, et al., 2005; De Soto and 
Deng, 2006). This drug is currently not available in SA. 
1.3. SPORADIC AND HEREDITARY COLORECTAL CANCER 
1.3.1. SPORADIC COLORECTAL CANCER  
Colorectal cancer (CRC), also called colon cancer or bowel cancer is a common cancer 
affecting both males and females. Cancer commonly arises from benign adenomatous polyps 
in the colon. Both genetic and environmental influences play a role in the development of 
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CRC Burt (1996) found that potentially definable genetic components exist in 15-35% of 
CRCs and the remaining 65- 85% are sporadic. 
1.3.1.1. Incidence 
In SA, CRC affects all ethnic groups. The NCR‟s report on the incidence of CRC between 
1998 and 1999 showed significant differences between the various ethnic groups in SA 
(White, Black, Asian, and Coloured). Differences between genders were also noted (Mqoqi et 
al., 2004). White males and females have a greater lifetime risk for CRC compared to the 
other population groups, and black males and females have the lowest risk for developing 
CRC in their lifetime (see Table 1.4). In 1999, CRC was found to be the fourth leading cancer 
in males (lifetime risk of 1 in 83) and the third leading cancer in females (lifetime risk of 1 in 
131) in SA (Albrecht, 2006; Mqoqi et al., 2004). 
Table 1.4: The lifetime risk of developing CRC for males and females in different SA 
population groups (statistics of CRC incidence in 1999, adapted from Mqoqi et al., 2004). 
 Females LR¹ for CRC Males LR¹ for CRC 
White 1/48 1/31 
Black 1/385 1/286 
Asian 1/99 1/51 
Coloured 1/89 1/56 
 
¹LR: Lifetime risk suggesting that every 1 in X number of individuals will develop cancer between the ages of 0-74 
years. 
1.3.1.2. Risk factors  
Various factors can increase an individual‟s risk of developing CRC. This cancer is more 
common in older individuals (older that 60 years of age). It is also known that certain types of 
polyps in the colorectum are more prone to cancer development that others. Other risk factors 
can be seen in Table 1.5. Protective factors include a healthy diet and a healthy lifestyle 
(Potter, 1999).  
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Table 1.5: Factors increasing an individual‟s risk for colorectal cancer (Reviewed in Mqoqi et 
al., 2004; Wogan et al., 2004; Chao, Thun, Connell et al., 2005; Park, Hunter, Spiegelman et 
al., 2005).  
 Risk factors 
Age  Risk of CRC increase with increasing age. Most common in 
individuals older that 60 years 
Genetic factors  Strong family history of CRC with a AD inheritance pattern 
 FAP and HNPCC mutation carriers 
Environmental 
factors 
 
 
 Alcohol consumption and smoking 
 Physical inactivity 
 High calorie diets with the intake of lots of animal fats including 
consuming over done red meat products 
 Virus exposure in particular human papilloma virus 
 
1.3.1.3. Detection and management  
CRC can be detected by making use of fecal occult blood test (FOBT), endoscopy, 
sigmoidoscopy, colonoscopy and stool DNA testing (sDNA) (Järvinen, Aarino, Mustonen, et 
al., 2000). Individuals in the general population should initiate screening modalities at 50 
years of age and every five years thereafter (CANSA, 2007).   
1.3.2. HEREDITARY COLORECTAL CANCER SYNDROMES 
Hereditary forms of CRC are due to the inheritance of a single altered gene which 
predisposes an individual to develop cancer. Two of the most common forms of hereditary 
CRC include familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal 
cancer (HNPCC) which account for <1% and 1-7% of all inherited CRC respectively (Burk, 
Petersen, Lynch, et al., 1997; Jo and Chung, 2005). Others include Gardner syndrome, Turcot 
syndrome, attentuated adenomatous polyposis coli (AAPC), and hereditary flat-adenoma 
syndrome (Lindor et al., 1998).  
1.3.2.1. Familial adenomatous polyposis 
Familial adenomatous polyposis (FAP) was one of the first inherited conditions identified 
that predisposes individuals to develop colorectal cancer (Kinzler, Nilbert, Su et al., 1991). 
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The disease affects the colon as well as the stomach, duodenum, jejunum and ileum 
(Goldberg, 1997). FAP is defined as the presence of more than 100 polyps (see glossary) in 
an individual‟s colorectum. The polyps appear in puberty and lead to clinical manifestations 
including diarrhoea, rectal bleeding and features of anaemia (Groden, Thliveris, Samowitz et 
al., 1991; reviewed in Järvinen, 2004). Approximately 66% of individuals carrying a FAP 
gene mutation will have cancer by a mean age of 39 years (Coleman and Tsongalis, 2002). 
Several other features such as congenital hypertrophy of the retinal pigment epithelium 
(CHRPE), dentiginous cysts and fundic gland polyposis of the stomach, periampullary 
carcinomas, osteomas, epidermoid cysts, thyroid cancer, brain tumours, and rarely 
hepatoblastomas are associated with FAP and can be indicative of this diagnosis (Coleman 
and Tsongalis, 2002; Lalloo et al., 2006).  
FAP follows an autosomal dominant inheritance pattern and is predominantly due to 
mutations in the adenomatous polyposis coli (APC) gene, a tumour suppressor gene situated 
on chromosome 5q21 (Kinzler et al., 1991). This gene encodes a 312 kDa protein with 
multiple domains binding with several proteins i.e. beta-catenin, axin, CtBP, Asefs, IQGAP1, 
EB1 and microtubules, to ensure normal cellular functioning (Aoki and Taketo, 2007). The 
mutations in this gene are predominantly due to premature truncation of the APC protein 
(Powell, Petersen, Krush et al., 1993). Individuals carrying this gene mutation have about a 
99% risk of carcinogenesis (Goldberg, 1997; Rozen and Macrae, 2006) and their offspring 
have a 1 in 2 or 50% risk of inheriting the gene. Over 826 germline mutations in the APC 
gene have been identified in FAP families and the mutation detection rate is estimated at 90% 
(Beroud, Collod-Beroud, Boileau et al., 2000; Solomon and Burt, 2007). The mutation most 
frequently found in FAP families in most population groups is a 5 base pair deletion in codon 
1309 of the APC gene. It is associated with an earlier age of presentation of colonic 
adenomas and a higher number of adenomas present in the colon (Bertario, Russo, Sala et al., 
2003; De Rosa, Scarano, Panariello et al., 2003). The above mutation and a 5 base pair 
deletion in codon 1061 have also been described in two African families (Xhosa and Zulu) 
although CRC incidence is lower in these individuals (Grobbelaar, Wilken, de Ravel et al., 
2002).  
Mutations in the Mut Y human homolog (MYH) gene on chromosome 1p34.1 are associated 
with a FAP like condition (attenuated form of FAP), affecting mostly Caucasian individuals, 
and presenting with a smaller number of adenomas (Baglioni and Genuardi, 2004). Disease 
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due to mutations in the MYH gene seems to follow an autosomal recessive inheritance pattern 
and therefore siblings of an individual carrying a MYH mutation are at 25% risk of also 
carrying this mutation (Baglioni and Genuardi, 2004).  
1.3.2.1.1. Surveillance and management for FAP mutation carriers 
Surveillance for at risk family members includes annual sigmoidoscopy from age 11 years 
and colonoscopy every 3-5 years (Lalloo et al., 2006). Screening should also include a 
gastroduodenoscopy (Coleman and Tsongalis, 2002; Chen, Phillips, Grist, et al., 2006). If any 
of the symptoms appear before the age of 10 years, screening and appropriate management 
should commence immediately.  
In the case of a FAP mutation carrier, prophylactic colectomy or protocolectomy with ileal 
pouch-anal anastomosis is recommended at age 20-25 years or 5 years earlier than the 
youngest affected family member (Coleman and Tsongalis, 2002).  
1.3.2.2. Hereditary non-polyposis colorectal cancer 
Hereditary non-polyposis colorectal cancer, also known as Lynch syndrome (Lynch, Shaw, 
Magnuson et al., 1966; Lynch, Smyrk and Lynch, 1997) is the most common hereditary form 
of CRC (Hadley, Jenkins, Diamond et al., 2004). Unlike FAP, HNPCC is not defined by 
multiple polyps, although some polyps may be present. With this condition, tumours mainly 
arise from a single colorectal lesion and occur more frequently in the proximal colon 
(Rijcken, Hollema, Kleibeuker et al., 2002). This condition occurs in approximately 1 in 3000 
individuals (Firth and Hurst, 2006). Diagnosis of HNPCC can be clinically suspected if one 
of two standardised set of criteria are met: Amsterdam 1 (Vasen, Mecklin, Khan et al., 1991) 
revised to Amsterdam 2 (Vasen, Watson, Mecklin et al., 1999), and Bethesda criteria 
(Rodriguez-Bigas, Boland, Hamilton et al., 1997) (See Table 1.6.)  
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Table 1.6: Amsterdam I, II and Bethesda criteria for clinical diagnosis of HNPCC. 
 
Amsterdam I criteria: (Vasen et al., 1991). 
 Colorectal cancer confirmed histologically in at least three relatives, one being 
a first degree relative (FDR) of the other two 
 Disease occurrence in at least two successive generations 
 Age of diagnosis earlier than 50 years in at least one individual 
 Exclusion of FAP 
Amsterdam II criteria: (Vasen et al., 1999). 
At least three relatives diagnosed with a HNPCC-associated cancer (colorectal, 
endometrial, ovary, stomach, hepatobiliary, small bowel, brain, ureter or renal 
pelvis and skin), tumours histologically verified where possible.  
Including the presence of the following criteria: 
 One case a FDR of the other two 
 At least two successive generations affected 
 At least one case diagnosed before the age of 50 
 Exclusion of FAP 
Bethesda criteria: (Rodriguez-Bigas et al., 1997).  
 Amsterdam criteria must be met in family 
Or 
 Two HNPCC related malignancies, including synchronous and meta-chronous 
colorectal cancers or associated extra-colonic cancers 
Or 
 Individuals with colorectal cancer and one FDR with colorectal cancer and/or 
HNPCC related extra-colonic cancers and/or a colorectal adenoma 
            Cancer diagnosed < 45 years and adenoma < 40 years. 
Or  
 Individuals in the family with: 
            Colorectal and endometrial cancer at age < 45 years 
            Cancer in proximal colon with an undifferentiated pattern < 45 years 
            Adenomas diagnosed at < 40 Years. 
 
HNPCC follows an autosomal dominant inheritance pattern and genes causing this particular 
syndrome include hMLH1, hMSH2 (Nicolaides, Papadopolous, Liu et al., 1994), hMSH6 and 
other rarer genes hMLH3, hPMS1 and hPMS2 (Kolodner, Hall, Lipford et al., 1995). These 
genes are all considered to be mismatch repair genes (MMR). Mutations in both the hMSH2 
                                            CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
 16 
gene (on chromosome 2p22-p21) and the hMLH1 gene (on chromosome 3p21.3) account for 
more than 90% of HNPCC cases, whereas mutations in the hMSH6 gene account for about   
1-7% of HNPCC cases (Peltomaki, Lothe and Aaltonin, 2003). About 5% of mutations in 
hMLH1 and 20% of mutations in the hMSH2 gene are large deletions or genetic 
rearrangements (Wagner, Barrows, Wijnen et al., 2003). By sequencing the hMLH1 and 
hMSH2 genes, mutation detection rates are 90-95% and 50-80% respectively (Wagner et al., 
2003; Pistorius, Gorgens, Plaschke et al., 2006). Tumours of these mutation positive 
individuals seem to show microsatelite instability (MSI) meaning that DNA replication is 
error-prone (Peltomaki et al., 1993; Coleman and Tsongalis, 2002). 
Individuals that test positive for a HNPCC mutation are also at risk for extra-colonic 
malignancies such as endometrium, ovary, small intestine, biliary tract, ureter, renal pelvis, 
stomach and pancreas (Möslein, Krause-Paulus Hegger et al., 2000). Those individuals that 
test positive for the hMLH1 and hMSH2 specifically will have a risk of about 80% for males 
and 40-60% for females of developing CRC by 70 years of age (Mitchell, Farrington, Dunlop 
et al., 2002).  
1.3.2.2.1. Surveillance and management for HNPCC mutation carriers  
HNPCC mutation carriers are advised to have colonoscopies every 2-3 years from the age of 
20-25 years, a modality which in turn will half their risk for CRC and reduce the chance of 
death due to cancer by 65% (Lalloo et al., 2006). Since adenomas in the colorectum are 
known to grow rapidly and are usually the reason for cancer, surveillance is important as they 
can be removed early (Vasen, Nagengast and Khan, 1995). Women should also have annual 
gynaecologic examinations (endometrial and ovarian) from the age of 30 years. Finally 
prophylactic colectomy, hysterectomy and oophorectomy are measures available to reduce 
the risk of cancer in mutation positive individuals. 
Screening of other sites such as, small intestine, biliary tract, ureter, renal pelvis, stomach and 
pancreas should also be considered if indicated in a specific family (Coleman and Tsongalis, 
2002).  
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1.4. GENETIC COUNSELLING 
The genetic counselling process is defined as: “the process of helping people understand and 
adapt to the medical, psychological, and familial implications of the genetic contributions to 
disease. The process integrates:  
 Interpretation of family and medical histories to assess the chance of disease 
occurrence or recurrence  
 Education about inheritance, testing, management, prevention, resources and research 
 Counselling to promote informed choices and adaptation to the risk or condition” 
(Resta, Biesecker, Bennett et al., 2006, pp 79) 
Genetic counselling is provided by appropriately trained professionals including genetic 
counsellors, clinical geneticists and genetic nurse counsellors. Patients with a variety of 
genetic conditions, including several cancer syndromes, are expected to benefit from this 
service.  
1.4.1. Cancer genetic counselling 
Over the last couple of years the demand for cancer risk assessment and predictive testing for 
individuals with a personal and/or family history of cancer has increased rapidly (Kausmeyer 
et al., 2006). Therefore, cancer genetics programmes have been established to provide 
patients at risk with a genetic counselling service.  Kelly (1991) and Schneider and        
Marnane (1997) described these cancer services using the term cancer risk counselling.  
Cancer risk counselling can be defined as a “communication process regarding an 
individual‟s possible increased risk of developing specific forms of cancer and includes 
obtaining detailed family, medical, and lifestyle histories, documentation of cancer-related 
diagnoses, pedigree construction and analysis, risk assessment and counselling, and 
discussion of options for early detection and prevention” (Schneider and Marnane, 1997, pp 
98). Once all the information is obtained and documented, the patient‟s risk can be assessed 
by using various risk calculation guidelines, e.g. Gail, Claus, Ford or Tyrer models for BRCA 
and Amsterdam I/II and Bethesda criteria for CRC (Gail, Brinton, Byar et al., 1989; Claus, 
Risch and Thompson, 1994; Vasen et al., 1999; Laloo et al., 2005).  
 
                                            CHAPTER 1: INTRODUCTION AND LITERATURE REVIEW 
 
 18 
1.4.2. Genetic testing procedures for cancer susceptibility genes 
Cancer genetic counselling services also include the option of facilitating genetic testing for 
various cancer susceptibility genes. Individuals and families in the moderate and high risk 
categories may be offered genetic testing. However, testing should only be offered after a 
complete pre-test counselling session, which includes a discussion about the benefits and 
limitations, ethics and implications, as well as medico-legal issues of genetic testing 
(Coleman and Tsongalis, 2002). Once the patient gives informed consent and is emotionally 
able to cope with any result, testing can proceed.  
At present in SA testing for HBOC is available for the three founder Ashkenazi Jewish and 
the three founder Afrikaner mutations at the Cancer Genetics Group, Human Genetics 
Section, University of Pretoria. Families and individuals without this ancestry can also get 
tested by means of sequencing both the BRCA1 and BRCA2 genes for disease causing 
mutations.  However, this service is currently only offered on a research basis (Personal 
communication, L van Rensburg, Cancer Genetics Group, Human Genetics Section, 
University of Pretoria). Another SA laboratory which offer BRCA founder mutation testing is 
the Division of Human Genetics, University of Free State. If individuals are found to test 
negative for the three common Ashkenazi Jewish or three Afrikaner mutations they can be 
offered further screening which includes the screening of exon 11 in the BRCA1 gene and 
exons 10-11 in the BRCA2 gene. They can also have screening of the complete BRCA1 and 
BRCA2 genes (Personal communication, N.C. van der Merwe, Division of Human Genetics, 
University of Free State). Blood samples can also be sent overseas to several laboratories for 
complete BRCA1 and BRCA2 sequencing.   
Since the 1980‟s, Ramesar, Madden, Felix et al (2000) have studied 500 HNPCC probands 
from the coloured population of the Northern Cape. Molecular studies on these individuals 
revealed a founder mutation, C1528T in the hMLH1 gene. This particular predisposing 
mutation was extensively researched and is also found to be associated with an increased risk 
of extracolonic cancers in female carriers (Felix, Bodmer, Fearnhead et al., 2006; Blokhuis, 
Goldberg, Pietersen et al., 2007). Testing for HNPCC (including the three common genes: 
hMLH1, hMSH2 and hMSH6) is done on a research basis at the Human Genetics Research 
Unit, University of Cape Town; but has been promised as a diagnostic service in the near  
future (Human genetics research unit, colorectal cancer project, 2008) The APC gene causing 
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FAP is analysed at the Division of Human Genetics, University of Stellenbosch on a research 
basis.  
Genetic testing can be complicated by variable expression of the gene, heterogeneity, 
polymorphisms, and penetrance of mutations. The tests are expensive, and can have various 
psychological, legal, and social consequences (Nakamura, Grody and Wu et al., 2004), and 
therefore it is important for each of these issues to be considered during a predictive genetic 
test consultation. Once test results are available a post-test genetic counselling session is 
arranged and it is recommended that a patient bring a support person to this session. At this 
appointment the test results, consequences of the results, and options available regarding 
management are discussed in detail. Emotional support is provided during the entire process 
and patients are referred to psychologists and various cancer support groups for further 
support if indicated. Insurance discrimination, coverage, and stigmatisation of genetic testing 
for inherited cancer susceptibility is misperceived, and more research is needed to fully 
understand this topic (Kausmeyer et al., 2006).  
1.4.3. Current status of cancer genetic counselling services in SA 
Medical genetic services in SA were established in the 1950‟s, when individual physicians 
with an interest in medical genetics provided genetic counselling (Jenkins, 1990). Currently 
genetic counselling services are provided in the major cities of SA including Cape Town, 
Bloemfontein, Pretoria, Durban and Johannesburg with outreach services to other cities, 
smaller towns and rural areas.  The Division of Human Genetics, University of the 
Witwatersrand and NHLS is currently providing genetic counselling services at three 
academic hospitals (Johannesburg Hospital, Chris Hani Baragwanath Hospital and 
Coronation Women and Children‟s Hospital) and a private hospital (The Donald Gordon 
Medical Centre) in Johannesburg and at various outreach clinics (Port Elizabeth, East 
London, Polokwane). Between January 2001 and December 2007, approximately 66 referrals 
for breast cancer, 41 for colorectal cancer and 33 for cases of cancer in the family have been 
documented at the Clinical and Counselling Section, in the Division of Human Genetics,  
University of the Witwatersrand and NHLS in Johannesburg and the numbers are increasing 
rapidly (Database of the Clinical and Counselling Section of the Division Human Genetics, 
University of the Witwatersrand and the NHLS, Johannesburg).  
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1.5. GENERAL PRACTITIONERS AND HEREDITARY CANCERS 
General practitioners are considered to be the primary health care facilitators providing a 
service to the community. They are easily accessed and tend to be the „middle man‟ between 
patients and specialists. GPs are involved in long term care of patients and their families and 
deal with many complex conditions, and therefore they seem to be ideally placed to play an 
active role in the "new genetics" by detecting at risk individuals and families and referring 
them appropriately (Mann, 2001; Brownson, Davis, Simms, et al., 1993).  
1.5.1. Knowledge, attitudes and practice of GPs regarding cancer genetics 
Several studies have explored the knowledge and attitudes of GPs regarding genetics and 
genetic testing and found that GPs have limited knowledge of genetic conditions and 
practices but accept that they have an escalating role to play in participating in “new 
genetics” (Emery, Watson, Rose et al., 1999; Fry, Campell and Gudmunsdottir et al., 1999; 
Bathurst and Huang, 2006). Other studies specifically related to cancer genetics, more 
specifically breast cancer and ovarian cancer, revealed that GPs referred low risk individuals 
to genetic services and seem to have unrealistic expectations of what happens at cancer 
genetic clinics (Watson, Clements and Yudkin et al., 2001; Pichert, Dietrich, Moosemann et 
al., 2003).  
Widerhoff, Vadaparampil, Greene et al (2005) suggested that basic knowledge of cancer 
genetics is vital for efficient assessment and management of risk for the appropriate health 
care of patients. They added that doctors should decide when it would be suitable to refer 
patients to other specialities like genetic counsellors and medical geneticists.  
A detailed family history is considered to be an essential tool to identify individuals and 
families at risk for a hereditary cancer and to separate them into the three risk categories 
(average, moderate, high risk). Several protocols exist to assist GPs in assessing cancer risks. 
These protocols also include recommended management options (Lalloo et al., 2006). Once 
individuals are recognised as being at high risk they should be referred to a cancer genetic 
counsellor for a further detailed family, medical and cancer history assessment, as well as 
counselling and possible testing. A study reviewing patients‟ files and doctors‟ notes, 
determined that nearly all patient records studied documented a presence or absence of a 
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family history of cancer.  The information did not contain enough detail to permit cancer risk 
assessment (Tyler and Snyder, 2006).   
Bathurst et al (2006) suggested that public awareness about rapid advances in cancer genetics 
and inherited cancer syndromes will increase the demand for genetic services and testing. For 
this reason more GP involvement is warranted in order to assess patients and families at risk 
and refer them appropriately. It is expected that GPs will directly order genetic tests for 
cancer susceptibility in the future (Escher and Sappino, 2000). No research on the topic has 
been found in the SA context. 
1.6. MOTIVATION FOR THE STUDY 
In SA, when someone is ill or has any medical enquiries e.g. cancer in the family, the first 
and most likely medical professional they will consult is their GP. Bearing this in mind, it is 
important to know how much GPs know about cancer genetics, and whether they offer 
referral for cancer risk counselling and cancer susceptibility testing. The literature revealed 
that a clear understanding of general principles that apply to hereditary cancers is important 
(Widerhoff et al., 2005). It is important to be able to identify at risk individuals and families, 
refer them, and manage them appropriately.  
 
Since the Clinical and Counselling Section, Division of Human Genetics, NHLS and 
University of the Witwatersrand is establishing a cancer genetics service it will be of great 
value to assess the GPs‟ understanding and practices with regards to cancer genetics. This 
research project was therefore designed to assess the practice, knowledge and attitudes of 
GPs in Johannesburg regarding hereditary cancers to establish whether there is need for 
further research and/or educational programs for GPs and whether GPs showed an interest in 
learning more about hereditary cancer and cancer susceptibility testing. 
1.7. AIMS AND OBJECTIVES OF THE STUDY 
Objective: To determine practices, knowledge, and attitudes of GPs in Johannesburg 
regarding common hereditary cancers using a questionnaire.  
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Aims: 
 To explore the practices of GPs regarding cancer screening, inherited cancer 
susceptibility testing and referral of patients to other specialities.  
 To assess the knowledge of GPs regarding inherited cancer, genetic counselling and 
genetic testing for specific hereditary cancer genes and concepts. 
 To explore the attitudes of GPs regarding hereditary cancer susceptibility testing 
recommendations.  
 To assess if there are differences between male and female GPs as well as those in  
single and multiple practices regarding their practices, knowledge, and attitudes 
concerning hereditary cancer. 
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CHAPTER 2 
METHODOLOGY 
 
This chapter describes the materials and methods used to conduct this research. It includes 
the research design, research tool, ascertainment and selection of the study subjects, data 
collection and data analysis.  
 
2.1. RESEARCH DESIGN 
 
A quantitative, exploratory research design was chosen, as the study was aimed at 
determining the practices, knowledge, and attitudes of GPs in the Johannesburg area, 
regarding common hereditary cancers. 
 
Quantitative research is focussed on the collection of numerical data (Brink, 1999). In a 
quantitative survey a formally structured questionnaire is used as a research tool to gather 
specific information from a research population (Brink, 1999).  
 
The objectives of an exploratory study include exploration of the dimensions of a 
phenomenon and the way it manifests, thus providing more insight (Brink, 1999). An 
exploratory research design was best suited to address the aims of this study e.g. to explore 
the subject‟s practices, knowledge and attitudes regarding cancer genetic screening 
procedures, cancer genetic susceptibility risk assessments and cancer genetic susceptibility 
testing.  
 
2.2. RESEARCH TOOL 
   
The research tool was a modified structured self-administered questionnaire (see appendix 
A). A questionnaire, designed and used by Widerhoff et al (2005) was modified for the 
purpose of this research. Widerhoff et al‟s (2005) questionnaire assessed knowledge about 
hereditary breast/ovarian and colorectal cancer amongst physicians in the United States of 
America. Their questionnaire was 12 pages long and consisted of 35 questions, divided into 
three parts: cancer susceptibility screening practices, attitudes regarding inherited cancer 
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susceptibility testing, and background and practice characteristics. Through electronic mail 
communication with Prof L Widerhoff (see Appendix B) authorisation was obtained to 
modify and use their questionnaire for this research project.  
 
The questionnaire was adapted to suit this particular study. Widerhoff et al (2005) conducted 
their research in the United States of America, thus demographic questions needed to be 
changed to suit the local context e.g. they asked if their participants were Latino or Hispanic, 
both ethnic groups that are not common in SA. Terminology relating to the professional 
designations, medical aid and practices were also changed in keeping with local practices e.g. 
Americans make use of the term health insurance plans whereas South Africans use the term 
medical aid plans. Finally the questions were re-organized into four sections to assess the 
participant‟s demographics (Part I), practices (Part II), knowledge (Part III) and attitudes 
(Part IV).  
 
The final questionnaire was seven pages long and had a total of 31 questions. Twenty-five of 
the questions were multiple choice questions and subjects were required to choose answers 
from a selection of options. Of these 25 multiple choice questions seven had additional space 
for the subjects to specify or elaborate on the answers they selected. The remaining 6 of the 
31 questions in the questionnaire, were open-ended.  
 
Part I: Your background and practice characteristics (Questions 1 to 8) 
This part included eight demographic questions about age, sex, qualifications, practice 
information, number of patients seen per week, and time spent in practice. The second last 
question in this section was to establish if the participant had had any family members 
diagnosed with cancer. The researcher asked this question to determine if there was a 
personal interest in familial cancer. The last question enquired as to whether the subjects had 
received any advertising materials regarding genetic testing for inherited cancer susceptibility 
in the past twelve months. The researcher wanted to know this information to test whether 
there was a correlation between increased knowledge regarding such services and having 
received advertising material.   
 
Part II: Practices in cancer susceptibility screening (Questions 1 to 11) 
This section consisted of eleven questions which assessed the subjects‟ practices regarding 
several cancer susceptibility screening procedures (Fecal occult blood test, Prostate-specific 
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antigen, Pap smear, clinical breast examination, mammography, CA-125 and abdominal 
ultrasound), family history information for new patients (self medical and cancer history, first 
and second degree relatives as well as ages of cancer onset), the number of patients interested 
in inherited cancer risk assessment and genetic testing as well as the subjects ordering and 
referring of cancer genetic tests, and finally their expectations of future usage of inherited 
cancer practices. 
 
Part III: Knowledge of genetic counselling and testing for inherited cancer. (Questions 1 to 
6). This section assessed the subjects‟ awareness of the availability and location of genetic 
testing and counselling facilities for several inherited cancer susceptibility genes, BRCA1/2, 
hMLH1, hMSH2, APC. The subjects‟ knowledge about several cancer genetic concepts was 
assessed by asking them about their knowledge of the inheritance of BRCA genes, the 
percentage of breast cancer cases accounted for by BRCA genes and the penetrance of 
HNPCC.  
 
 Part IV: Attitudes on inherited cancer susceptibility testing (Questions 1 to 6).  
Six multiple choice questions were posed to assess the attitudes of the participants regarding 
their interest in providing genetic counselling, assess which factors influence their decisions 
to use genetic tests for inherited cancer susceptibility and about which basic genetic tests for 
inherited cancer concepts they are aware.  
 
2.3. PILOT STUDY 
 
After the research tool was adapted, a pilot study was conducted to test the questionnaire. A 
pilot study according to Last (2002) is “a small-scale methodological test intended to ensure 
that proposed methods and procedures will work in practice before being applied…” The 
purpose of the pilot study in this project was to improve the research tool, to establish 
whether the questions posed were understandable and unambiguous. The pilot study also 
helped to establish the time it would take the participants to complete the questionnaire. The 
researcher also wanted to establish if the tool would provide enough relevant information to 
answer all the research questions and if the proposed method to collect the data was 
appropriate.  
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A medical practice in Johannesburg with 7 GPs was approached where 5 GPs agreed to 
participate in this pilot study. The participants reported that they understood all the questions 
in the questionnaire and thus no major corrections were required. In part IV of the 
questionnaire, question 1 was changed slightly. This was a question with 3 response choices 
(Yes, No and Don‟t know) The last mentioned option was removed because of ambiguity. 
The participants reported that the questionnaire took approximately 15 minutes to complete 
and no other suggestions were made.  
 
2.4. ASCERTAINMENT AND SELECTION OF STUDY SAMPLE 
 
The subjects selected were general practitioners (GPs) all of whom are part of a mailing list 
of the Department of Family Medicine (DFM), School of Clinical Medicine, Faculty of 
Health Sciences, University of the Witwatersrand (WITS), Johannesburg. These GPs are all 
in a private practice setting and involved in teaching post-graduate medical graduates.  
 
The researcher contacted the Head of Department of Family Medicine Prof B. Sparks, who 
facilitated the process. The contact list was made available to the researcher. It consisted of 
212 GPs and included postal and physical practice addresses. The subjects‟ offices were 
contacted in order to confirm their postal or physical addresses, before a research package 
was mailed. The final study sample comprised 196 GPs because some GPs had emigrated, 
relocated or retired. A research package was posted that included a research cover letter from 
the Head of Family Medicine, an information sheet, a response sheet, 2 self addressed 
envelopes and the seven-page questionnaire (Appendix  A and C1-3)                                                                       
 
2.5. DATA COLLECTION 
 
In this research project, the postal service was used as a distribution method and the research 
package was mailed to the 196 subjects. They were initially given four weeks to complete the 
questionnaire and response sheet, and return the provided self-addressed envelopes to the 
researcher. Separate envelopes were provided to maintain the subjects‟ anonymity so that 
their answers could not be linked to their personal information, but the researcher could keep 
track of who had responded so that they were not contacted again. 
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The first completed questionnaires were returned approximately a week after they were sent 
out and by the due date 26 (13%) of the questionnaires had been returned. As postal surveys 
tend to have a poor response rate of 10-50% (Neuman, 1997), the researcher devised 
strategies to increase the response rate. These included mailing a second research package 
containing a new positively worded cover letter (Appendix C2), the questionnaire and two 
self-addressed envelopes. The subjects were then given three weeks to respond. This strategy 
was successful as an additional 35 questionnaires were received within 6 weeks. Thus a total 
of 61 (31%) completed questionnaires were received. Only one questionnaire was returned 
blank and seven research packages were returned by the post office because of post boxes 
being closed, wrong addresses or for other reasons not provided. The total time period over 
which data were collected was approximately three months.   
 
Once the completed questionnaires were received, they were given a unique identification 
number. The data from each of the questionnaires were then entered into an Excel database 
for analysis.  
 
2.6. ANALYSIS OF DATA  
 
Data from all 61 questionnaires were entered into the database and analysed using descriptive 
statistics, i.e. tables and cross tables, graphs and figures to facilitate an understanding of the 
research project‟s data (Brink, 1999). Frequency distributions, central tendency statistics 
associations and inference were also employed to gain an understanding of the study data. 
The subjects were divided into groups, namely males and females, and multiple and single 
practices, and the variables of these two groups were compared by using chi-squared and 
Fisher‟s exact tests (Fisher, 1935). The sample size was considered too small for further 
stratified analysis of age and personal experience/family history of cancer. The data were 
depicted graphically in graphs, histograms and tables.  
 
2.7. ETHICAL CONSIDERATIONS 
 
The research protocol was submitted and ethics approval was granted by the Human 
Research Ethics Committee (Medical), Faculty of Health Sciences, the University of the 
Witwatersrand, reference number: M070219 (Appendix D). 
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Anonymity of the GPs was maintained by not having any form of identification on the 
questionnaire and confidentiality was maintained as a separate response sheet 
obtaining the subjects‟ personal details as well as an opportunity to receive feedback 
on the research findings was provided. The subjects had to send the completed 
questionnaire and response sheet back in the two separate provided envelopes. Only 
the researcher had access to the completed questionnaires. 
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      CHAPTER 3 
                                                                    RESULTS  
 
3.1 INTRODUCTION 
 
In this chapter the results of the data collected from the 61 questionnaires are discussed. The 
data were analysed using descriptive statistics depicted in tables, cross tables, graphs and 
figures. This chapter consists of four parts namely demographics, practice, knowledge and 
attitudes. Comparisons were also made between the practice, knowledge and attitudes of GPs 
in single and multiple practices and between males and females as well as between subjects 
with personal experience of cancer and those with none. Although the sample size was small, 
a few significant differences between GPs in single and multiple practices and between males 
and females were found, and only these are presented in this chapter.  The sample size was 
too small for further stratified analysis of age and personal experience/family history of 
cancer. 
 
From a sample of 196 subjects, 62 responded and only 61 (31%) of the completed 
questionnaires were used for analysis. This is considered a reasonable response rate for a 
postal survey (Neuman, 1997). The researcher excluded incomplete questionnaires and those 
that were returned to the researcher by the post office due to wrong address or closed post 
boxes. These data are summarized in Table 3.1.  
 
Table 3.1: Summary of the sample  
Total number of subjects surveyed                                         196  
Completed research packages received 1
st
 round                         26 
Completed research packages received 2
nd 
 round                        35 
Incomplete research packages received                                          1 
Research packages returned to sender                                            8 
TOTAL research packages  returned                                            70                        
Excluded from research                                                                  9 
Final sample completed  
questionnaires useful for analysis                                              61                                                                                                                           
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3.2. PART I: GPs’ BACKGROUND AND PRACTICE CHARACTERISTICS AND 
ADDITIONAL INFORMATION 
 
3.2.1 Questions 1-6: Demographics. This section describes the study subjects‟ ages, gender, 
qualifications, number of patients seen and the total amount of hours spent in the practice.  
 
The respondents included 19 (31%) female subjects and 42 (69%) male subjects. The subjects 
ages ranged from 35 to 69 years of age with a mean age of 49 years and a standard deviation 
of 10. The average age of male GPs is 51 years old compared to the average age of female 
GPs being 47 years old (p= 0.12).All of the subjects have a Bachelor of Medicine and 
Surgery degree and 24 (39%) subjects reported having additional degrees (BSc, BPharm) or 
diplomas (DA, DCH, DTMH).  
 
About an equal number of subjects reported practising in a single (29, 48%) and a multiple 
(32, 52%) practice setting. The 61 subjects saw a median of 110 patients a week (range: 60-
400), of which a total of 50 were male and 60 female patients. This result shows that one GP 
saw 400 patients a week which means 80 patients a day. This GP reported practising in a 
multiple practice alongside four colleagues, this subject could have interpreted this question 
as the total number of patients seen in the practice and if so each would see about 20 patients 
a day. They spent on average 45 hours per week (range: 7-72) in their practice.  
 
3.2.2 Questions 7-8: Additional information. This section also obtained information on 
whether there were any cases of cancer in the subjects‟ families and if they had ever receive 
advertising material promoting cancer susceptibility testing.  
 
The subjects had to choose between 7 options. Three subjects chose more than one option, 
therefore in this particular question there were 67 responses. This question was posed to 
determine whether a personal experience of cancer would result in increasing interest in 
familial cancer. As can be seen in Figure 3.1, 22 (33%) of the subjects did not have any 
relatives with cancer, 16 (24%) had a first degree relative with cancer and 20 (30%) reported 
having affected second degree relatives. Therefore a total of 54% of subjects had a family 
member affected with cancer. None of the subjects reported that they had cancer themselves 
and 9 (13%) had partners affected with cancer.  
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n= 67: Some subjects chose more than one option, therefore 67 responses. 
FDR: First degree relative, SDR: Second degree relative 
Figure 3.1: Responses of subjects with regards to whether any of their family members were 
diagnosed with cancer.  
 
Figure 3.2 indicates that the majority of subjects (54, 86%) had never received any 
advertising material and very few (9, 14%) subjects have received any advertising material 
marketing genetic tests for inherited cancer susceptibility testing. Advertising material could 
have been obtained in person, by telephone, by mail, by electronic mail (internet).  
 
 
n= 63: Some subjects chose more than one option, therefore 63 responses. 
Figure 3.2: The number of subjects who received advertising material marketing genetic 
testing for inherited cancer susceptibility.  
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3.3. PART II: PRACTICES ON CANCER SUSCEPTIBILITY SCREENING 
 
3.3.1. Question 1: Cancer screening procedures used by the subjects. 
 
Population screening strategies are the most important tools for the early detection and 
diagnosis of cancer. The results regarding which screening tests the subjects in this study 
used are presented in Figure 3.3. The majority of the subjects reported that they mostly make 
use of the following screening modalities for 1 to 10 patients per month: prostate specific 
antigen (PSA) (56, 92%), Pap smear (53, 87%), clinical breast examination (58, 95%) and 
mammography (60, 98%). An abdominal ultrasound examination is used by 37 (61%) of 
subjects. The tests used in at least 1 patient per month or never by most subjects are faecal 
occult blood tests (FOBT) (41, 67%) and CA-125 (35, 57%).  
 
 
* Significant difference between subjects in single and multiple practices (p= 0.002) 
The numbers (n) of responses by subjects are shown on the bars  
Figure 3.3: Subjects‟ monthly usage of cancer screening procedures. 
 
The responses of subjects regarding their practices of cancer screening procedures in single 
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cancer screening procedures was found in this category.  This result showed that 79% 
(n=23/29) of subjects in a single practice use a Pap smear for >10 pt/month compared to the 
41% (n=13/32) of subjects in a multiple practice that use this test for > 10 pt/month (χ² = 
12.69, df = 3, p = 0.002). 
 
3.3.2. Question 2: Information that the subjects gather from their new patients.  
 
As can be seen in Figure 3.4, 84% (n= 51) of subjects ask >10 „new‟ pt/month for medical 
and cancer history information. An equal number of subjects reported also asking for medical 
and cancer history information on their patients‟ first degree relatives (FDR). The results 
show that the subjects are less likely to enquire about their patients‟ second degree relatives‟ 
(SDR) medical and cancer history information and the ages at diagnosis of cancer for both 
FDR and SDR.  
 
 
The numbers (n) of responses by subjects are shown on the bars 
FDR= First degree relatives, SDR= Second degree relatives  
Figure 3.4: The number of new patients who are asked medical and family cancer history per 
month. 
 
3.3.3. Question 3-5: Patients‟ interest in cancer risk assessment and testing. 
 
Patients see GPs for several health reasons. Thirty four (56%) of the subjects reported that   
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because of their family history. Only 2 (3%) subjects reported that they had never been asked 
the question. The subjects were asked how frequently during the last 12 months their patients 
asked them about their hereditary cancer risks compared to previously and interestingly 70% 
(n= 43) of the subjects selected the “remained the same” response.  
 
Fifty one percent (n= 31) of the subjects reported that they had patients who asked them if 
they could or should get tested for an inherited cancer susceptibility. 
 
3.3.4. Question 6-9: The subjects‟ use of cancer genetic testing.  
 
The majority of subjects (46, 75%) reported not assessing whether their patients were 
candidates for cancer genetic testing. The remaining 15 (25%) subjects, who did assess their 
patients‟ risks, assessed on average about 10 patients risks per year. Thirty percent (n= 18) of 
the subjects ordered genetic tests for inherited cancer susceptibility compared to the 70% (n= 
43) that did not. The research assessed what proportion of the subjects refer patients 
elsewhere for cancer genetic testing and/or risk assessment and 36% (n= 22) have referred 91 
patients. The above results are all displayed in Figure 3.5. 
 
 The numbers (n) of responses by subjects are shown on the bars  
Figure 3.5: Subjects practices regarding cancer genetic testing. 
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Responses can be seen in Figure 3.6 as to where subjects refer their patients for further risk 
assessment and genetic testing for inherited cancer susceptibility.  The category “other” 
includes Breast Cancer Clinics, Oncology Clinics and various specialists e.g. 
gastroenterologists. Half (32, 52%) of the subjects did not respond when asked to name a 
facility.  
 
 
Figure 3.6: Response of the subjects as to where they refer patients for inherited cancer 
susceptibility services.  
 
3.3.5. Question 10-11: Subjects‟ expectations for future research. 
 
The majority, 39 (64%) of the subjects expect that the number of patients who will undergo 
genetic testing for inherited cancer susceptibility will increase within the next 5 years, 
compared to 11 (18%) who predict that it will remain the same, and 22 (36%) that indicated 
they are unsure what will happen. 
 
The subjects also reported that they expect to be directly involved in the ordering of genetic 
tests for breast and ovarian cancer (48, 79%) and CRC (47, 77%) in the future, and 7 (11%) 
expect to request genetic testing for other cancers such as lung cancer and prostate cancer 
(see Figure 3.7). 
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 The numbers (n) of responses by subjects are shown on the bars  
Figure 3.7: Subjects responses to the types of cancers for which they expect to be ordering 
genetic susceptibility testing.  
 
3.4. PART III: KNOWLEDGE ON GENETIC COUNSELLING AND GENETIC 
TESTING FOR INHERITED CANCER 
 
3.4.1. Questions 1-3: Participants‟ knowledge of genetic counselling, of genetic testing 
facilities and tests for cancer genes.  
 
The results from these questions are summarized in Table 3.2. The Division of Human 
Genetics, University of the Witwatersrand and NHLS is currently the only facility in 
Johannesburg that provides genetic counselling services specifically for inherited cancer 
susceptibility. Thirty eight percent (n= 23) of the subjects were aware of the availability of 
genetic counselling facilities and 27% (n= 17) correctly named the NHLS. The other subjects         
(10, 16%) named other facilities (Lancet Laboratory, Pretoria Academic and Cancer clinics or 
Specialist clinics) and 58% (n= 37) did not respond.  
 
In Gauteng, genetic testing for some inherited cancer syndromes is available at the Cancer 
Genetics Group, Human Genetics Section, University of Pretoria. Only after genetic 
counselling does the Division of Human Genetics, University of the Witwatersrand and 
NHLS provide a testing service through the Cancer Genetics Group, Human Genetics 
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Section, University of Pretoria. This testing has not been on a commercial basis but rather 
through a research institution. 
 
Table 3.2: Knowledge of genetic counselling and testing facilities and cancer susceptibility 
genes. 
 Subjects 
   N                            %  
1. Availability of genetic counselling facilities                   n=61 
               Yes 
               No 
               Don‟t know 
Sites of counselling facilities*                                              n=64 
0. No answer 
1. Other # 
2. NHLS (SAIMR) 
3. PTA academic 
4. Lancet laboratories 
 
 
   23                          38 
   24                          39 
   14                          23 
 
   37                         58 
    4                           6 
   17                        26 
    3                           5 
    3                           5 
2. Availability of genetic testing facilities                           n-61 
              Yes 
              No 
              Don‟t know 
Sites of genetic testing facilities*                                         n=68 
0. No answer 
1. Other # 
2. NHLS (SAIMR) 
3. PTA academic 
4. Lancet laboratories 
 
 
   32                        52 
   16                        26 
   13                        21 
 
   29                        42 
     8                         12 
   17                        25 
    4                           6 
   10                        15 
3. Availability of commercial testing for cancer susceptibility 
genes  n=61                                               
       a.    BRCA1 and BRCA2 genes 
              Yes 
              No 
              Don‟t know 
 
       b.    hMSH2 and hMLH1 genes 
              Yes 
               No 
               Don‟t know 
 
        c.   APC gene 
             Yes 
             No 
             Don‟t know 
 
 
 
   28                       46 
    0                          0  
   33                       54 
 
 
     8                       13 
     0                         0 
   53                       87 
 
 
     9                       15 
     0                         0 
   52                       85 
 *Some subjects’ reported more than one genetic counselling and genetic testing facility 
# Other includes: breast cancer clinics, support groups and specialist physicians (gastro-enterologists, oncologists) 
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The researcher found that approximately half of the subjects (32, 52%) knew about the 
availability of these genetic testing facilities. Only 6% (n= 4) of the subjects were aware of 
Pretoria‟s genetic testing facilities and 25% (n= 17) reported the NHLS. A large group of the 
subjects (29, 43%) did not respond when asked to name the site of a genetic testing facility; 
15% (n= 10) and 12% (n= 8) selected incorrectly Lancet Laboratory and others (Breast 
Cancer Clinics, Oncology Clinics and various specialist clinics e.g. Gastroenterology Clinics) 
respectively. In SA limited genetic tests are available for both the BRCA genes in HBOC, as 
well as for the hMLH1 and hMSH2 genes in HNPCC and for the APC gene in FAP and none 
are commercially available. Testing the knowledge of the subjects regarding the availability 
of testing for these 5 genes most of the subjects, (28, 46%) were aware that there are genetic 
tests available for the BRCA1/2 genes. The majority of the subjects were unaware of genetic 
testing for hMLH1, hMSH2 (53, 87%) and the APC (52, 85%) gene.  
 
3.4.2. Questions 4: Inheritance of BRCA genes 
 
About the same number of subjects responded “yes” (27, 44%) correctly and “don‟t know” 
(33, 54%) and 1 (2%) responded “no” to the question: “Suppose you have a female patient 
whose aunt or grandmother on her father‟s side carries the BRCA1 gene mutation for HBOC, 
in your opinion could your patient also be a carrier of this mutation?” This suggests that 
nearly half of the subjects knew that individuals can inherit BRCA gene mutations from their 
fathers, as these are autosomal dominant mutations.   
 
3.4.3. Questions 5: Percentage of BRCA mutations in breast cancer  
 
About 5-10% of breast and ovarian cancers are due to the genetic predisposing genes, BRCA1 
and BRCA2. Eighteen (30%) subjects accurately responded that less than 10% of females 
with breast cancer are at risk of carrying a BRCA1 or BRCA2 mutation, compared to             
31 (50%) that did not know. The other subjects responded inaccurately.  
 
3.4.4. Question 6: Penetrance of HNPPC genes 
 
The majority of the subjects (46, 75%) did not know what the penetrance of the HNPCC 
genes are. Only 3 (5%) selected the correct 50-100% response.  
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3.5. PART IV: ATTITUDES ON INHERITED CANCER SUSCEPTIBILITY 
TESTING RECOMMENDATIONS 
 
This section explored the subject‟s attitudes regarding inherited cancer susceptibility testing 
recommendations.  
 
3.5.1. Question 1: Providers of genetic counselling 
 
Genetic counselling is a service that provides patients with information on genetic testing and 
their risks for inherited cancer. The subjects were asked to indicate which health care 
providers they feel can provide a genetic counselling service (see Figure 3.8).  All 61 (100%) 
of the subjects reported that registered genetic counsellors are qualified to provide genetic 
counselling. They also thought that clinical geneticists and oncologists could provide this 
service, possibly suggesting that the oncologist will provide genetic counselling equivalent to 
the clinical geneticist who has training in genetic counselling. Interestingly most of the 
subjects (40, 65%) indicated that they did not see themselves as competent to provide genetic 
counselling. 
 
 
 The numbers (n) of responses by subjects are shown on the bars  
Figure 3.8: Subjects‟ responses regarding health care professionals thought to be qualified to 
provide genetic counselling. 
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3.5.2. Question 2: Factors that play a role in deciding the use of genetic tests for inherited 
cancer susceptibility 
 
The subjects were given 10 factors regarding genetic tests for inherited cancer susceptibility 
and asked to indicate which ones influence their decision. The data were collapsed into three 
groups namely important (very important and somewhat important), not important (not very 
important and not important at all) and don‟t know, and the results are presented in            
Figure 3.9.  
 
Ninety eight percent (n= 60) of the subjects reported that a patient‟s cancer risk profile is 
important (2a). Eighty percent (n=49) reported that they take a patient and their family‟s 
attitudes towards genetic testing for inherited cancer susceptibility into consideration when 
deciding to offer them cancer genetic testing (2b). The other factors which seem to play an 
important role in the subjects‟ decision to use genetic testing for inherited cancer 
susceptibility were information resources including guidelines in their practice, discussions of 
cases between colleagues and guidelines from medical societies (each equal responses of 50, 
82%), continuing medical education (56, 92%), clinical data from medical literature (54, 
88%) and lastly training in medical schools and their internship years (44, 72%) (2c-f, h,j).  
 
What is notable in question 2g, was that the majority (39, 64%) of the subjects thought that 
commercial advertisements and promotions were not important. This factor does not 
influence their decision to use genetic testing for inherited cancer susceptibility. In question 
2i asking about the importance or not of coverage of genetic tests by their patient‟s medical 
aid plans, equal numbers of the subjects thought medical aid coverage was important and not 
important. 
 
Furthermore the researcher also looked to see if there were any differences between the 
attitudes of the subjects in two categories: male and female and single and multiple practices. 
Significant results were found in question 2j and 2h. In question 2j, males thought that cancer 
genetic training in medical school or during residency (internship) was important as opposed 
to the females who indicated it to be less important (χ² = 5.22; df = 2, p = 0.047). In 2h with 
regard to single and multiple practices, the researcher found that more subjects in a multiple 
practice felt that clinical data in the medical literature is important compared to those in a 
single practice (χ² = 8.075, df = 3, p = 0.037).  
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# Significant difference between the attitudes of male and female subjects (p = 0.047)  
* Significant difference between the attitudes of subjects in single and multiple practices (p = 0.037) 
The numbers (n) of responses by subjects are showed on the bars  
 
Figure 3.9: Subjects‟ attitudes regarding the role various factors, concerning genetic tests for 
genetic cancer susceptibility, play in their decision-making process to use cancer 
susceptibility testing.  
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3.5.3. Question 3: Statements regarding genetic tests for inherited cancer susceptibility 
 
This question asked the importance of several statements regarding genetic tests for inherited 
cancer susceptibility and a likert scale was used to gather the information. The results can be 
seen in Table 3.3. 
 
Table 3.3: Subjects‟ attitudes regarding the role various inherited cancer susceptibility testing 
statements play in their practice.                                        
                                                                                     Numbers and percentage (%) of GP’s 
 Agree 
n                 % 
Disagree 
n                  % 
Don’t know 
n                  % 
Clear guidelines (3a) 
Testing availability (3b) 
Testing cost-effective (3c) 
Risks are clear (3d) 
Genetic testing  ambiguous (3e)* 
Medical aid cover (3f) 
Confidentiality (3g) 
Insurance discrimination (3h) 
Genetic counselling before testing (3i) 
21               34% 
27               45% 
10               16% 
26               42% 
7                 12% 
0                   0% 
15               25% 
43               70% 
57               93% 
18             30% 
13             21% 
16             26% 
18             30% 
13             21% 
24             41% 
36             59% 
7               12% 
3                 5% 
22              36% 
21              34% 
35              58% 
17              28% 
41              67% 
36              59% 
10              16% 
11              18% 
1                  2% 
 
* Significant difference between the attitudes of male and female subjects (p = 0.031) 
 
Fifty seven percent (n= 35) of the subjects responded that they did not know if genetic testing 
of patients with a family history of cancer is cost-effective because inherited mutations are 
rare (3c). Sixty seven percent (n= 41) and 59% (n= 36) of the subjects were unsure whether 
genetic tests for inherited cancer susceptibility have too many false positive, false negative, 
or ambiguous (3e) results and whether medical aid coverage is available for these tests (3f).  
 
The statement, 3h, that patients with positive test results are at risk for insurance 
discrimination (43, 70%), and 3i, that patients should not have genetic tests without having 
  CHAPTER 3: RESULTS 
 43 
had genetic counselling (57, 93%) were those that the subjects mostly agreed with. Thirty 
three percent (n= 21), 44% (n= 27) and 43% (n=26) of subjects agreed with statements 3a, 3b 
and 3d respectively. In question 3g, 70% (n= 43) disagreed with the statement: “It is difficult 
to ensure that patients test results will remain confidential.  
 
The attitudes between male and female subjects in this section were compared, and a 
significant difference was found only in question 3e; more male than female subjects reported 
that genetic tests for inherited cancer susceptibility have too many false positive, false 
negative, or ambiguous results (χ² = 6.71, df = 2, p = 0.031). 
 
3.5.4. Question 4: GPs‟ qualifications to recommend genetic testing 
 
The subjects were asked whether they considered themselves qualified to recommend genetic 
testing for inherited cancer susceptibility to their patients. The majority of subjects (46, 75%) 
felt that they were not qualified compared to 15 (24%) subjects that reported feeling that they 
are somewhat qualified.  
 
3.5.5. Questions 5-6: GPs‟ interest in continuing medical education in cancer genetics 
 
Most (53, 87%) subjects indicated that they are very/somewhat interested in receiving 
continuing medical education in genetic risk assessment and testing for cancer susceptibility 
(Figure 3.10). One subject who responded „not very interested‟ stated that he would be 
retiring soon but thought that the field of cancer genetics was “fascinating”.  
 
With regards to guidelines, almost all of the subjects, (60, 98%) indicated that they feel that 
there is a need for guidelines on cancer genetics for general practitioners.  
 
Finally the subjects were given a separate response sheet where they had to indicate whether 
they wanted a summary of the results after completion of the project and 84% (n= 51) 
responded that they did. This suggests that the majority of subjects are interested in gaining 
more information about this project and cancer genetics. 
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Figure 3.10: Subjects interest in receiving continuing medical education in genetic risk 
assessment and testing for inherited cancer susceptibility (Question 5). 
 
3.6. SUMMARY 
The data from 61 completed questionnaires were analysed and the results showed that more 
male than female subjects participated in the research and about equal numbers of subjects 
practiced in single or multiple practices. Sixty eight percent of the subjects reported that they 
have never received advertising material about cancer genetic testing and the majority of 
subjects were not aware of genetic testing and counselling facilities in their geographic area.  
 
The results also showed that the subjects seem to obtain limited information on cancer history 
in their patients‟ for SDRs and age of onset. Only a few subjects assessed their patients‟ risk 
for inherited cancer susceptibility and even less refer their patients to other facilities for risk 
assessment and genetic testing.  
In the section, on knowledge, the results showed that subjects seemed to be more aware of 
BRCA genes than of CRC genes and concepts. The subjects‟ attitudes to genetic testing for 
inherited cancer susceptibility were assessed. Several factors, such as patient history and 
family attitudes to testing, as well as information from several medical facilities, played an 
important role in the subjects‟ decision to make use of genetic testing for inherited cancer 
susceptibility. Information from commercial advertisements did not play an important role in 
their decision making process. The majority of the subjects were unsure about the costs of 
31 (51%)
22 (36%)
5 (8%) 3 (5%) Very interested
Somewhat interested
Not very interrested
Don't know
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cancer genetic tests and about interpretation of the results. Many thought positive test results 
would lead to insurance discrimination, and that all individuals who want testing must have 
genetic counselling. With respect to the subjects‟ practice of their use of cancer screening 
procedures and attitudes about genetic tests for inherited cancer susceptibility, a few 
significant differences between the attitudes of male and female subjects as well as between 
the groups single and multiple practices were found and reported on. Finally the subjects 
reported that they mostly do not see themselves as suitably qualified to recommend genetic 
tests for inherited cancer susceptibility. They also indicated a need for general practitioner 
guidelines about cancer genetics. 
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                                                              CHAPTER 4                                            
 
                                                               DISCUSSION  
 
The results of this study show that amongst GPs in Johannesburg genetic counselling and 
testing facilities are not well known. The GPs are unfamiliar with the cancer genetic concepts 
tested such as the inheritance of BRCA1/2 genes, the percentages of breast cancer cases with 
either BRCA1 or BRCA2 genes and the penetrance of HNPCC genes. They also rarely make 
use of cancer genetic services. However, the GPs reported interest in receiving guidelines to 
assist them in cancer risk assessment and referral practices.      
 
4.1. PART 1: DEMOGRAPHICS OF THE SAMPLE  
 
More males than female GPs participated in the project (2:1 ratio). Since the male: female 
ratio in GPs in Johannesburg was unknown the researcher cannot comment on why this 
occurred.  Because more male than female GPs were qualified before the year 2000, it might 
have been expected that more male GPs would participate in this study (Breier and 
Wildschut, 2006).  
 
The subjects‟ ages ranged from 35 to 69 years, suggesting that the youngest participant could 
have completed her medical school training in 1998 and the oldest his training in 1964. This 
strengthens the above statement that it is more likely that older male GPs would have 
participated in the study compared to the female GPs. 
 
This study also looked at the categories single versus multiple GP practices to determine if 
there are any differences between the practice, knowledge and attitudes of these GPs. The 
results showed that about the same numbers of GPs practiced alone (29, 48%) and together 
with colleagues (32, 52%). There seem to be no information in the literature about GPs 
practicing alone and in multiple practices in SA.  
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4.2. PART II: CANCER SUSCEPTIBILITY SCREENING PRACTICES 
 
4.2.1. Use of cancer screening procedures 
 
Cancer screening procedures are used to allow early detection of cancer leading to early 
intervention and management. An encouraging finding in this study was that GPs are 
involved in cancer prevention practices as they commonly make use of several cancer 
screening modalities by either performing screening tests themselves e.g. clinical breast 
examinations, or by referring patients elsewhere for cancer screening tests. This finding 
subsequently demonstrates that GPs are willing to take part in cancer-prevention.  
 
The subjects were asked on how many asymptomatic patients per month they performed 
specific cancer screening tests on, or referred elsewhere. The results showed that GPs use 
CBEs (58, 95%), mammography (60, 98%), Pap smears (53, 87%) and abdominal ultrasound 
examination (37, 61%) for 1-10 patients per month and they reported using CA-125 for at 
least 1 patient per month or never. The cancer screening test more commonly used for males 
seems to be a PSA test, which 92% (n= 56) of GPs use for 1 – 10 patients per month.  
 
For both males and females FOBT is used to detect CRC and it seems that the GPs do not use 
this test as commonly as the other cancer screening tests (see Figure 3.3). As a FOBT is 
proposed to be a cost-effective, noninvasive screening method, and has been shown to reduce 
CRC mortality by about 16% (Walker, 2007), it is uncertain as to why the subjects do not 
make use of this test as readily as other screening methods. One reason could be because this 
test shows low sensitivity and specificity and high false positive and negative results (Bond, 
2002). Walsh and Terdiman (2003) showed that GPs make use of sigmoidoscopies or 
colonoscopies since both of these tests show improved detection of both small and large 
colorectal lesions. As these two mentioned tests were not included as options in this study, 
the subjects‟ use of these could not be evaluated.  
 
4.2.2. Information gathering 
 
This study found that 84% (n= 51) of subjects ask medical and family cancer history of the 
individual patient and their first degree relatives, but less often obtain this information on 
second degree relatives and also seems to rarely document the ages of cancer onset in the 
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family (22, 36%). In order to calculate an individual‟s risk for cancer susceptibility, a 
complete three generation family history needs to be obtained. A history needs to include 
information about cancer types and diagnosis in every affected individual as well as the ages 
of cancer onset, as there is a strong association with inherited cancers and multiple affected 
family members, as well as earlier ages of onset. The majority of GPs from this study do not 
seem to obtain enough information and thus would not necessarily be able to assess their 
patient‟s risks for inherited cancer susceptibility accurately. However, it should be noted that 
38% (n= 23) of GPs do seem to gather appropriate family histories as they document cancer 
history in multiple generations as well as the ages of cancer onset in affected individuals.  
 
Tyler et al (2006) found that information in patient records from several medical practices 
was not enough for correct cancer risk assessments, correlating with this study‟s findings. 
These results are of concern as at risk patients may not be identified and therefore not 
appropriately referred. The researcher feels that there is a need to educate GPs about the 
importance of obtaining a complete family history, which could be done by providing them 
with cancer risk assessment tools using cancer pamphlets as guidelines.  
 
4.2.3. Interest of GPs’ patients in hereditary cancer 
 
Watson et al (2001) studied GP referrals to the Oxford Regional Genetic Service. In one 
question they enquired as to who initiated discussions about familial cancer and the results 
showed that in most of the cases it was the patient who usually initiated a discussion on 
familial cancer and also requested referral for risk assessment and testing. This study found 
that 56% (n= 34) of the GPs reported that between 1 -10 patients per month asked about their 
individual cancer risk, as they had a family history of cancer. The GPs reported that currently, 
compared to previously, there is no increase in the number of patients asking about familial 
cancer risks. This suggests that the general population does not seem to have an increasing 
interest in or awareness of hereditary cancers. The researcher anticipates increasing interest 
of the general public in hereditary cancers with time and awareness. The literature anticipates 
an increasing interest and demand for genetic services and testing as the public are becoming 
more aware and knowledgeable about hereditary diseases, including cancers (Kirk and 
Kefford, 2000; Watson et al., 2001; Sanderson, Wardle, Jarvis, et al., 2004).  
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4.2.4. Use of genetic tests for inherited cancer susceptibility  
 
Considering that 51% (n= 31) of GPs have been asked by their patients if they could get 
tested for inherited cancer susceptibility, it would be expected that more GPs would have 
assessed their patients‟ risks. However, it was found that only 25% (n= 15) of the GPs 
determined whether their patients were candidates for cancer genetic testing, compared to the 
75% (n= 46) that did not assess risks. It is probable that the GPs are unfamiliar with cancer 
risk assessment methods and therefore do not assess risk for inherited cancer susceptibility.  
 
Widerhoff, Freedman, Olson et al., (2003) investigated primary and secondary care 
physicians‟ use of cancer susceptibility testing. They explored whether their subjects ordered 
cancer susceptibility testing or referred patients for testing and/or risk assessment. Their 
study found that only 33% of their subjects made use of cancer susceptibility tests. Similarly, 
this study found that 30% (n= 18) and 36% (n= 22) of the GPs reported that they order 
genetic tests for cancer susceptibility and refer patients elsewhere
 
for testing or assessment 
respectively. As direct cancer susceptibility tests are generally not available to the GPs in SA, 
it is not unexpected that the majority of subjects (43, 70%) did not order any cancer 
susceptibility tests during the past 12 months prior to completing this survey. A concern is 
what GPs regard as a genetic test for inherited cancer susceptibility, as they could have 
confused a genetic test for cancer susceptibility with a cancer screening tests such as 
mammography or colonoscopy. 
 
There are facilities available for assessment of patient risks for inherited cancer susceptibility, 
which include the Division of Human Genetics, NHLS and the University of the 
Witwatersrand. In the case of genetic testing for inherited cancer susceptibility, testing is 
mostly available on a research basis rather than diagnostically as a service through academic 
institutions for example the Human Genetics Division, University of Pretoria and the 
Division of Human Genetics, NHLS and the University of Free State.  This is not entirely 
surprising as it is not a commercially available service. Lucassen, Watson, Harcourt et al 
(2001) examined the influence that referral guidelines have on GPs and their practices, 
and found that these increase the number of appropriate referrals to genetic clinics. This 
suggests that if referral guidelines are distributed to the subjects from this research they may 
refer at risk patients to genetics clinics.  
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4.2.5. Expectations for future use of cancer genetic tests 
 
The majority of the subjects (39, 64%) predicted that the number of their patients who will 
make use of cancer genetic tests will increase in the next 5 years and they expect to be 
requesting cancer susceptibility tests for BRCA, OC, CRC, prostate and lung cancer, 
suggesting that GPs expect to be more active in ordering genetic testing for inherited cancer 
susceptibility. Several other studies found that the general public is becoming more aware of 
the availability of cancer susceptibility tests and an increase in demand for testing is predicted 
(Fry et al., 1999; Escher et al, 2000; Pichert et al, 2003). 
 
4.3. PART III: GPs’ KNOWLEDGE  
 
Widerhoff et al., (2005) proposed that basic knowledge regarding cancer genetics is essential 
to accurately assess and manage individuals and families at risk for a hereditary cancer. 
Based on the results of this study it seems that many GPs are unfamiliar with several cancer 
genetic concepts and did not know about the availability of genetic counselling and testing 
facilities.  
4.3.1. Location of counselling and testing facilities and testing for inherited cancer 
genes. 
Patients with inherited cancer syndromes were seen occasionally at the Division of Human 
Genetics, NHLS and the University of the Witwatersrand, Johannesburg prior to 2001. 
Numbers however have increased since 2001 probably due to an increasing knowledge of 
inherited cancers in both the public and the medical profession. According to this study, GPs 
were more aware of genetic testing services (32, 52%) than genetic counselling services (23, 
38%) that are available in their area. Few GPs (9, 14%) reported ever having received any 
advertising material promoting genetic tests for inherited cancer susceptibility (see Figure 
3.2) and therefore it was not surprising that they are not aware of genetic testing facilities. 
Also, genetic testing for inherited cancer is currently not readily available in SA. These 
results suggest that GPs have limited knowledge of genetic counselling services in their area 
and it could also suggest limited knowledge of the role genetic counselling plays in other 
genetic disorders.  
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Fifty eight and 43% of GPs did not respond when asked to provide a name of a genetic 
counselling and testing facility respectively, or they named an incorrect facility. Only 27% 
were aware that the Division of Human Genetics, University of the Witwatersrand and 
National Health Laboratory Service is the only facility in Johannesburg that provides genetic 
counselling for inherited cancer susceptibility. Six (10%) of the subjects still referred to the 
Division of Human Genetics, University of the Witwatersrand, NHLS as the South African 
Institute of Medical Research which indicates that they are not familiar with the name change 
of this institution in the year 2000. The Division of Human Genetics, University of the 
Witwatersrand, NHLS provides a service for genetic testing for inherited cancer susceptibility 
using the Human Genetics Division, University of Pretoria. Only 25% (n= 17) and 6% (n= 4) 
of GPs knew about these services in Johannesburg and Pretoria respectively. As so few GPs 
knew about the correct counselling and testing facilities it is suggests that they are unaware of 
these services. It could also suggest limited knowledge regarding the role of genetic 
counselling services not only for inherited cancers but also for other genetic disorders. This 
implies a need for the Division of Human Genetics, University of the Witwatersrand and 
NHLS to promote their genetic services in JHB, Gauteng and ideally throughout the whole of 
SA. Also there is a need for diagnostic genetic testing services for inherited cancer 
susceptibility.  
 
Overall, the GPs were more aware of the availability of genetic testing for HBOC cancer 
susceptibility genes, BRCA1/2 (28, 46%) than for HNPCC, hMLH1 and hMSH2 (8, 13%) and 
FAP, APC (9, 15%). They may be more aware of HBOC testing than CRC testing, because 
breast cancer receives more coverage in the media; the South African Government, 
Department of Health declared the month of October the official breast cancer awareness 
month. These services are also more available. Also in the past a private testing facility 
proactively promoted their genetic testing services for breast cancer by giving lectures on 
inherited breast cancer testing to health professionals. With increasing public awareness in 
BRCA, patients are enquiring more about their risks and testing options.   
 
4.3.2. BRCA1/2 inheritance, hereditary breast cancer population risk and HNPCC 
penetrance 
 
Of concern is that only 27 (44%) GPs in this study were aware that BRCA1/2 mutations can 
be inherited through the paternal as well as the maternal line, 18 (30%) understood that these 
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mutations occur in <10% of breast cancer cases, and 31 (50%) of the subjects were uncertain 
of the percentage of the BRCA1/2 mutations in breast cancer patients. Only 3 (5%) identified 
penetrance of HNPCC mutations correctly as being > 50%, and 46 (75%) of the subjects 
were unaware of the penetrance.  
 
The results show that the GPs participating in this study, seem to have limited knowledge of 
both the HBOC syndrome and CRC genetic concepts tested. These findings were comparable 
to those of Widerhoff et al‟s., (2005) who assessed the knowledge of USA physicians 
regarding basic cancer concepts. Widerhoff et al (2005) suggested that the reason for this 
could be that cancer susceptibility genes were only discovered relatively recently and it is 
thus expected that the GPs are unfamiliar with cancer genetic concepts. Also, most of the GPs 
surveyed would not have been taught about hereditary cancer genes and concepts during their 
training in medical school. Other studies also noted limited knowledge of GPs regarding 
hereditary cancers (Escher et al, 2000; Watson et al., 2001; Rose, Watson, Yudkin, et al., 
2001). This in turn would influence the GPs role in identifying individuals at risk for an 
inherited cancer, initiating risk assessment, referral and management.  
 
4.4. PART IV: GPs ATTITUDES ABOUT INHERITED CANCER SUSCEPTIBILITY 
TESTING  
 
4.4.1. Genetic counselling. 
 
It is encouraging to note that all of the GPs (61, 100%) responded in this section that they felt 
a genetic counsellor is the most qualified to provide genetic counselling; followed by a 
clinical geneticist (52, 85%) and oncologist (42, 69%). It is possible that the use of the term 
genetic counselling in the question was leading and thus contributed to so many doctors 
(100%) providing genetic counsellors as one of their answers. However, they also thought 
that clinical geneticists and oncologists were suitable health care professionals to provide 
genetic counselling, which remains encouraging. This result could be somewhat in conflict 
with the fact that only a few GPs were aware of the availability of genetic counselling 
facilities (see Table 3.2). Just because GPs are knowledgeable about who can provide genetic 
counselling does not mean that they know where genetic counselling services are available.   
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Elwyn and Gray (2000) reported that GPs are not interested in providing genetic counselling. 
In their study 65% (n= 40) of the GPs stated that they do not feel equipped to provide genetic 
counselling.  Fry et al (1999) also found that GPs did not want to counsel patients about 
cancer risks. Several studies looked at possible reasons why GPs do not want to counsel 
patients about inherited cancers and consistently found that they reported that they do not 
have time to provide a medical as well as a counseling session during a consultation (Fry et 
al., 1999; Escher et al., 2000; Bathurst et al., 2006). This study confirmed that the subjects 
have time limitations with each consult, since they reported spending ±45 hours per week in 
practice seeing a median of 110 patients weekly.  If GPs work a 5 day week, they would 
spend about 9 hours per day seeing ±22 patients a day for ±25 minutes each. If this is 
compared to the duration of a genetic counselling session, (where a session is approximately 
60 minutes, where ±20 minutes of the session is allocated to obtain a family history and draw 
a complete 3 generation family tree), it can be acknowledged that the subjects do not have 
enough time to spend with each patient in order to do a complete family history, genetic risk 
assessment and genetic counselling.  
 
4.4.2. Factors influencing GPs decision to use cancer susceptibility testing. 
 
With respect to which factors influence the GPs‟ decisions to use genetic tests for inherited 
cancer susceptibility they acknowledged most of the factors as being important.  Firstly, the 
GPs responded that an individual patient‟s cancer risk profile (60, 98%) and   attitudes 
towards genetic testing (49, 80%) are important. Secondly, the GPs felt that information and 
guidelines from several institutions: their practices (50, 82%), government societies/agencies 
(50, 82%), published data in medical literature (54, 88%), continuing medical education (56, 
92%) and training in medical school (44, 72%) are important.  
 
In contrast, 64% (n= 39) of the subjects responded that commercial advertisements and 
promotions are not important. Since advertising for hereditary cancers has been relatively 
limited this finding was not surprising. However, as testing for genetic susceptibility becomes 
more available diagnostically or predictively the use of commercial advertisements may 
become a key factor to publicity awareness. Vadaparampil, Widerhoff, Olsen et al (2005) 
referred to commercial advertisements as additional sources of information and found that 
their subjects thought of such information sources as important. It would therefore be 
valuable for the Division of Human Genetics, University of the Witwatersrand and NHLS to 
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note that when setting up an awareness campaign to advertise their genetic testing and 
counselling services for inherited cancer susceptibility, that more than one way of 
advertisement and awareness should be used to approach GPs e.g. personal contact with the 
GPs should be made, as well as the implementation of commercial advertisements and 
promotions. 
 
With regards to the role that training in medical school plays it was significant that male 
subjects thought it was more important than did the female subjects (p= 0.047). Since cancer 
susceptibility genes were only discovered relatively recently, this information has only been 
incorporated into medical school training since then. Today even only the basic information 
about genetics, in particular cancer genetics, is taught in medical schools in SA. Therefore the 
older GPs participating in this study would not have been taught about inherited cancer genes 
and the availability of testing and counselling for at risk individuals during their training in 
medical schools. Since in this study male GPs were on average older (although this was not 
significant) it was surprising that the male GPs reported their training in medical school to be 
an important factor which would assist them to recommend genetic tests for cancer 
susceptibility. 
 
There was also a significant difference in responses between GPs practicing alone and those 
practicing in a multiple practice. It seems that clinical data from medical literature was more 
important to those subjects in a multiple practice, whereas subjects in a single practice 
reported it to be not important (p= 0.037).  It could be that GPs in a single practice have their 
own guidelines and patient management protocols, in contrast to the GPs in a multiple 
practice that make use of guidelines from medical literature. Also GPs in a multiple practice 
are more open to discuss new medical findings with their colleagues.  
 
4.4.3. Subjects’ statements regarding genetic tests for inherited cancer susceptibility. 
 
It is recommended that patients have genetic counselling prior to any genetic testing (Harper, 
2005). A genetic counsellor will empower the counselee with information regarding the 
testing procedures, discuss the advantages and limitations of the tests as well as provide 
emotional support throughout the whole process. Ninety three percent (n= 57) of the GPs 
agreed with the statement that suggested that patients should not have genetic tests without 
having genetic counselling.  
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Dickens, Pei, and Taylor (1996) suggested that those individuals who test positive for genetic 
susceptibility may be at increased risk for disability, life insurance and employment 
discrimination. This study determined that the majority of the subjects (43, 70%) strongly 
agreed that patients with positive test results for inherited cancer susceptibility are at risk for 
insurance discrimination.  In a study done by Freedman, Wideroff, Olson, et al (2003) which 
also explored physicians‟ attitudes towards genetic testing for cancer susceptibility, it was 
found that 81% of their subjects responded that positive test results lead to insurance 
discrimination. The World Health Organisation‟s (WHO) Guidelines on Bioethics (1999) 
stated that: “Genetic information should not be used as the basis for refusing employment or 
insurance”. The above is also similar to UK guidelines (Williams, Skirton and Masny, 2006). 
No evidence of insurance discrimination with regards to inherited cancer susceptibility has 
been found in SA. Discrimination has been observed in other chronic conditions e.g. HIV 
positive status (Aids Law Project, 2008).     
 
About equal numbers of GPs agreed (21, 34%) and did not know (22, 36%) that there are 
guidelines available for managing positive cancer susceptibility patients. Similarly, 43% (n= 
26) agreed that risks for a patient who tested positive for an inherited cancer susceptibility 
gene are clear. This suggest that GPs seem to have some idea of interpreting and managing 
genetic test for inherited cancer susceptibility results. Again it is concerning as to what their 
understanding is about genetic tests, as they could be understanding it to be cancer screening 
tests rather then genetic tests. Forty four percent (n= 27) of GPs agreed that genetic testing 
services are readily available. In response to a different question noted in this study 52% (n= 
32) reported that they are aware of genetic testing facilities available.  
 
Forty one (67%) of the GPs were unsure whether a genetic test for inherited cancer 
susceptibility has inaccurate or ambiguous results. It is significant that more male subjects 
were unsure about the statement that “genetic tests for inherited cancer susceptibility has too 
many false positive, false negative or ambiguous results” compared to the female subjects 
who (p= 0.031). This finding could suggest that many GPs do not understand the 
interpretation of genetic test results. 
 
Fifty seven percent (n= 35) and 67% (n= 41) of GPs were also unsure about the costs and 
coverage of genetic tests by medical aid schemes. Some medical aid schemes are known to 
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cover patient‟s genetic tests but it is not well known which ones and it is thus the patient‟s 
responsibility to consult with their medical aids before genetic testing is to be performed.    
 
Thirty six (59%) GPs disagreed with the statement “it is difficult to ensure that patients test 
results will remain confidential”. This suggests that the majority of GPs feel they can ensure 
confidentiality of their patients‟ medical information. In a similar study, Freedman et al 
(2003) found that 47% of their subjects agreed that patient confidentiality could be ensured 
compared to the 53% that thought it was difficult to ensure confidentiality of patient test 
results.   
 
4.4.4. Attitudes about and interest in cancer susceptibility testing 
 
Zielinski (2005) found that about 60% of primary care physicians in the United States of 
America don‟t feel qualified to recommend testing themselves. The current study found that 
75% (n= 46) of GPs do not feel qualified to recommend cancer genetic testing. This may be 
due to limited knowledge, limited training or lack of awareness of the facilities which offer 
testing. It could also be seen as a reason why the subjects in this study rarely make use of 
cancer genetic testing (see figure 3.5).  
 
GPs accept that they have an increasing role to play in cancer genetic services. They are 
prepared  to participate in family history taking, deciding which patients to refer for genetic 
testing and to manage cancer predisposed patients. However, they were found to be 
unfamiliar with cancer risks calculations and cancer genetic counselling (Fry et al., 1999). In 
this study 87% (n= 53) of GPs expressed interest in learning more about specific areas of 
inherited cancer genetics, including genetic risk assessment and testing for inherited cancer 
susceptibility but as seen previously they do not see themselves fit to provide genetic 
counselling.  
 
It was encouraging to find that 98% (n= 60) of the GPs felt a need for guidelines and 84% 
(n= 51) requested a report of the research findings, indicating that GPs in Johannesburg are 
interested in receiving education about cancer genetics and are interested in playing a role in 
such services in the future. An educational program, providing GPs with informational 
booklets, cancer genetic pamphlets and educational lectures could thus be designed. 
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                                                             CHAPTER 5 
 
                                            SUMMARY AND CONCLUSIONS 
 
 
This chapter covers the summary of the research with reference to the aims and objectives of 
this study, limitations in this study and recommendations for future research as well a 
conclusion.  
 
5.1. SUMMARY  
 
With reference to the first aim of this study which was to explore the practices of GPs 
regarding cancer screening, inherited cancer susceptibility testing and referral of patients to 
other specialities this study found the following:  
 GPs seem to use several cancer screening procedures frequently e.g. clinical breast 
examinations, mammograms, PSA and Pap smear. They seem to use CA-125 and 
FOBT less often. 
 They do not obtain enough family history information from their patients and thus 
would not necessarily be able to assess cancer risks accurately. 
 Although many of the GPs patients were found to be interested in cancer risk 
assessment and genetic testing for inherited cancer, GPs were found to assess their 
patients risks rarely and also rarely refer patients to have genetic testing for inherited 
cancer susceptibility. 
 Most GPs expect to be directly involved in the ordering of genetic testing for inherited 
cancer susceptibility for breast cancer, colorectal cancer, prostate cancer and lung 
cancer in the future. 
 
The second aim was to assess the knowledge of GPs regarding inherited cancer, genetic 
counselling and genetic testing for specific hereditary cancer genes and concepts. With 
regards to this aim the research found: 
 Many GPs are not aware of the availability of genetic counselling and testing 
facilities. 
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 The majority of GPs know that genetic tests for HBOC are available but the minority 
know about the available genetic tests for HNPCC and FAP. These tests are not 
available diagnostically in SA, but only on a research basis.   
 Nearly 50% of the GPs were unaware of the transmission of BRCA1 gene through the 
paternal as well as the maternal line and also were uncertain of the percentage of 
female patients with breast cancer who will have BRCA1/2 mutations. 
 Many GPs were unaware of the penetrance of HNPCC mutations. 
 
With reference to the third aim of this study which was to explore the attitudes of GPs 
regarding hereditary cancer susceptibility testing recommendations the following were found: 
 Although the question was posed in a leading manner all of the GPs felt that a genetic 
counsellor is the most qualified to provide genetic counselling followed by a clinical 
geneticist and oncologist but not themselves. 
 The majority of GPs reported the following factors to be important: 
- an individual patient‟s cancer risk profile 
- patients‟ and families‟ attitudes towards genetic testing 
- information and guidelines from several institutions: their practices, 
government societies/agencies, published data in medical literature, continuing 
medical education, and training in medical school 
 Most GPs responded that commercial advertisements and promotions are not 
important and they were unsure about the involvement of patients medical aid plans 
when it comes to coverage of such tests. 
 Nearly all of the GPs indicated that all patients should have genetic counselling before 
they have any genetic testing. 
 Most GPs agreed with the statements that: 
- genetic testing services are readily available 
- risks for patients who test positive are clear 
- individuals who test positive for genetic susceptibility may be at increased risk 
for insurance discrimination 
 The majority of GPs are unsure about whether:  
- a genetic test for inherited cancer susceptibility has inaccurate or ambiguous 
results 
- genetic testing is cost effective 
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- medical aids cover genetic tests for inherited cancer susceptibility 
- clear guidelines are available to manage patients with positive test results 
 Only about half of the GPs feel they can guarantee confidentiality of their patients‟ 
medical information. 
 Only one quarter of the GPs feel qualified to recommend genetic tests for inherited 
cancer susceptibility but they feel there is a need for guidelines and furthering their 
training. 
 The majority of the GPs wanted a summary of this research report. 
 
The final aim was to assess if there are differences between male and female GPs as well as 
those in a single and multiple practices regarding their practices, knowledge, and attitudes in 
hereditary cancer: 
 Significantly more male GPs consider the information about inherited cancers which 
they learn in medical school training as important compared to the female GPs. 
 Clinical data from medical literature was more important to those subjects in a 
multiple practice, whereas subjects in a single practice reported it to be not important. 
 It was significant that more male subjects were unsure whether a genetic test for 
inherited cancer susceptibility has inaccurate or ambiguous results compared to the 
female subjects who seemed to understand the interpretation of genetic test results 
better. 
 
5.2. LIMITATIONS 
 
During the course of this study certain limitations became evident and are listed below: 
 As the GPs were affiliated with an academic institution and thus motivated, the 
sample could have been biased. Therefore their practice, knowledge and attitudes may 
not be representative of other GPs who are not affiliated with an academic institution.  
 The sample size was small and only 61 GPs participated in the project which made 
statistical analysis limiting. 
 The study was conducted in the Johannesburg area and therefore the findings cannot 
be generalised to other parts of SA.  
 The study was conducted in English and in a multilingual society the language barrier 
may influence the accuracy of some of the answers.  
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 The GPs might have answered the survey in a way of social desirability and thus this 
may have caused bias. 
 The subjects were not asked to give reasons for the answers they provided and the 
discussion of the results in this section is therefore mostly speculation.  
 When the subjects were asked about their practice in cancer genetic procedures, 
colonoscopy was not included and this limited the researcher‟s ability to assess their 
use of surveillance for CRC.  
 The subjects were asked about commercial genetic testing. It is difficult to judge their 
answers as no real commercial testing is available, although some testing is available 
on a limited service basis. 
 
5.3. RECOMMENDATIONS  
 
 Since this study showed that GPs thought continuing medical education is a valuable 
resource to learn more about inherited cancer, an educational and awareness program 
should be initiated to educate GPs on cancer genetic risk assessment (taking a three 
generation family history, age of cancer diagnosis and type of cancer including 
histology information) and the availability of genetic testing and counselling facilities 
for inherited cancer susceptibility. The educational program can take place by 
providing GPs with informational letters, pamphlets and talks and the information 
addressed should include appropriate family history. Ultimately this may improve the 
management of “at risk” individuals and increase referral rates to the correct genetic 
counselling and testing facilities. 
 
5.4. FUTURE RESEARCH 
 
 The literature mostly compares the knowledge and attitudes regarding hereditary 
cancers between different specialists and GPs. Future research could therefore focus 
on the practice, knowledge and attitudes of different health care providers especially 
specialist doctors and compare the findings with the findings of this study.  Including 
in this, cancer risk assessment could be further explored. 
 Once the Division of Human Genetics, University of the Witwatersrand and NHLS 
has initiated educational interventions and guidelines to assist GPs with risk 
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assessment and referral for inherited cancer patients, it would be valuable to test their 
knowledge of genetic tests for inherited cancer susceptibility and to re-assess whether 
referral rates increase and what impact this would have on testing and counselling 
services. Specialists e.g. oncologists, gastroenterologists could also be educated about 
risk assessment and referral for inherited cancer susceptibility. 
 It would also be interesting to establish what the general public‟s awareness and needs 
are with regards to inherited cancers, by assessing their understanding of hereditary 
cancer, their interest in receiving more information and also their attitudes regarding 
genetic testing for inherited cancer susceptibility.  
 The Division of Human Genetics, University of the Witwatersrand and NHLS could 
conduct an audit on the records of patients seen for genetic counselling regarding 
inherited cancer to establish what is currently happening in this service and where 
improvements can be made.  
 A larger sample could be used and this research can be conducted in other areas of 
Gauteng or the greater SA.  
 
5.5. CONCLUSIONS 
 
In conclusion, it seems that many GPs have limited knowledge of both genetic testing for 
inherited cancer and the availability of facilities to provide genetic testing and counselling, 
however they reported interest in learning about these services and expect to play a role in 
cancer genetic services in the future.  
 
The findings suggest that there is a need to educate GPs about the basic concepts in cancer 
susceptibility screening and testing. This enable them to identify those at risk for inherited 
cancer syndromes, provide information about the genetic tests currently available for 
inherited cancer susceptibility and available genetic counselling and testing facilities. 
Awareness and educational programs could be done by distributing cancer genetic 
information pamphlets, referral guidelines and/or with informational lectures to the GP. 
Future research could be focused on assessing the use of these educational interventions. 
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PART II. PRACTICES ON CANCER SUSCEPTIBILITY SCREENING  
 
1. For asymptomatic patients of the appropriate age and sex, on how many patients per month do 
you perform or refer elsewhere each month for the following cancer screening procedures? 
Less than 1 patient each month, one to ten patients each month, more than ten patients each 
month, or never? (CHECK “NOT APPLICABLE” IF THE TEST IS NOT APPROPRIATE IN YOUR PATIENT 
POPULATION.) 
                                                                   >10 pt/month   1-10 pt/month   <1 pt/month       Never                                                                                                                                                       
a. Fecal occult blood test (FOBT)                                                                 
b. Prostate-specific antigen (PSA)                      
c. Pap smear                                                     
d. Clinical breast examination (CBE)              
e. Mammography                                            
f. CA-125                                                         
g. Abdominal ultrasound                               
 
2. How many new patients per month do you ask to provide the following information: (CHECK ONE BOX 
ON EACH LINE)  
                                                                  >10 pt/month    1-10 pt/month   <1 pt/month        Never                                                                                                                                                      
a. A medical history?                                                                            
b. A family history of cancer                      
   among first degree relatives,  
   such as parents, siblings, and children?                                           
c. A family history of cancer among       
   second degree relatives, such as  
   grandparents, aunts, and uncles?    
d. Age of diagnosis of      
   relatives with cancer?                       
 
3. How many patients per month ask you if they have an increased risk of cancer because of    
    their family history of cancer? 
     >10 pt/month        1-10 pt/month       <1 pt/month       never 
                                                                                                                                                   
4. During the past 12 months, have they asked you the above question more frequently, less  
    frequently, or the same as in previous years? 
   More frequently    less frequently    remained the same   don’t know  
              
5. During the past 12 months, have any of your patients asked you if they can or should get tested  
    for an inherited cancer susceptibility gene? 
   Yes   Approximately how many patients? __________   No 
 
6. During the past 12 months, have you assessed any of your patients’ personal and family  
     medical history to determine if they are candidates for genetic testing for inherited cancer  
     susceptibility? (Do not include patients whom you referred to another health care provider for  
     this assessment.) 
   Yes   Approximately how many patients? __________     No 
 
7. During the past 12 months, have you ordered a genetic test for inherited cancer susceptibility? 
   Yes            No  
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8. During the past 12 months, have you referred any of your patients to another health care     
    provider for a genetic test for inherited cancer susceptibility, or for an assessment of whether or    
    not they are candidates for genetic testing? 
   Yes  Approximately how many patients? __________       No     
 
9. To what kind of healthcare facility or provider did you refer them? 
______________________________________________________________________________ 
______________________________________________________________________________ 
 
10. During the next five years, do you expect the number of your patients who undergo genetic    
      testing for inherited cancer susceptibility to: (CHECK ONE BOX) 
    Increase substantially   Increase somewhat               Remain the same 
    Decrease somewhat      Decrease substantially          Don’t know 
 
For the next question, please respond Yes, No, or Not Sure 
11. In the next 5 years, do you expect to directly order, or refer patients elsewhere for, a genetic  
      test for inherited cancer susceptibility for: (CHECK ONE BOX ON EACH LINE) 
                          
                                                          Yes                No                 Not Sure 
a. Breast or ovarian cancer                     
b. Colon cancer                                       
c. Other  (Specify) _________________________________________________ 
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PARTIII. KNOWLEDGE ON GENETIC COUNSELLING AND GENETIC TESTING FOR 
INHERITED CANCER. 
 
1. Are there any facilities that can do genetic counselling for inherited cancer 
    susceptibility in the geographic area from which you draw your patients? 
   Yes         No         Don’t know 
    If you answered yes please name these facilities __________________________________ 
 
2. Are there any facilities that can do genetic testing for inherited cancer susceptibility in the  
    geographic area from which you draw your patients? 
   Yes         No         Don’t know 
    If you answered yes please name these facilities __________________________________ 
 
3. Based on your current knowledge, are tests for the following inherited cancer susceptibility  
    genes commercially available in South Africa? 
                                                                               Yes                   No                Don’t know 
a. BRCA1 and BRCA2 genes                                          
    for hereditary breast/ovarian syndrome.                                      
b. MLH1 and MSH2 genes for hereditary                   
    non-polyposis colorectal cancer (HNPCC).           
c. APC gene for familial adenomatous     
    polyposis (FAP).                                                   
 
4. Suppose you have a female patient whose aunt or grandmother on her father’s side carries the   
    BRCA1 gene mutation for breast/ovarian cancer syndrome. In your opinion, could your patient   
    also be a carrier of this mutation? (CHECK ONE BOX) 
       Yes                    No                Don’t know 
   
5. In your opinion, what percentage of female breast cancer patients have a BRCA1 or BRCA2  
    gene mutation? 
   Less than 10%    10 to 19%    20 to 49%     50 to 100%     Don’t know 
 
6. In your opinion, what percentage of patients who carry a gene for hereditary non-polyposis  
    colorectal cancer will actually go on to develop colorectal cancer? 
   Less than 10%   10 to 19%     20 to 49%     50 to 100%    Don’t know 
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PART IV. ATTITUDES ON INHERITED CANCER SUSCEPTIBILITY TESTING 
RECOMENDATIONS 
 
For the next question, please respond Yes, No, or Don’t know 
1. Genetic counselling provides patients with information on genetic testing and their risk for  
      inherited cancer. Who of the following health care provider(s) would you consider qualified to   
      provide genetic counselling to your patients? (CHECK ONE BOX ON EACH LINE) 
                                                         Yes                  No                  Don’t know 
a. Yourself                                                 
b. Clinical geneticist                                  
c. Oncologist                                              
d. Registered genetic counsellor                
Give a reason for your answer_____________________________________________________ 
 
2. If you were to use genetic tests for inherited cancer susceptibility, what role would each of the  
   following factors play in your decisions whether or not to recommend testing? Would they be   
   very important, somewhat important, not very important, not important at all, or don’t you know?       
   (CHECK ONE BOX ON EACH LINE) 
                                                     Very         Somewhat    Not Very    Not Important   Don’t know 
                                                    Important   Important     Important      at All                    
a. The individual patient’s cancer      
    risk profile                             
b. The individual patient’s or      
     their family’s attitudes toward 
     genetic testing                     
c. Recommendations and guidelines      
    from your institution or practice                        
d. Discussions with your       
    colleagues                                        
e. Recommendations and       
    guidelines from medical societies  
    or government agencies                       
f. Information you obtained through      
   continuing medical education            
g. Commercial advertisements and      
    promotions                                 
h. Clinical data published in the      
    medical literature                    
i. Coverage of genetic tests by your      
   patients’ medical insurance plans     
j. Your training in medical school,      
   residency                                           
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3. For each of the following statements concerning genetic tests for inherited cancer susceptibility, 
    indicate whether you strongly agree, somewhat agree, somewhat disagree, strongly disagree,     
    or don’t you know? (CHECK ONE BOX ON EACH LINE) 
                                                    Strongly     Somewhat     Somewhat    Strongly     Don’t know                                                                     
                                                     Agree         Agree             Disagree       Disagree     
 
a. Clear guidelines or strategies are      
    available for managing patients 
    with positive test results        
b. Genetic testing services are      
    readily available                                  
c. Genetic testing of patients with a      
    family history is cost effective 
    because inherited mutations are  
    rare                        
d. The risk of cancer in patients who      
     have a positive genetic test is 
     clear                     
e. Genetic tests for inherited cancer      
    susceptibility have too many false 
    positive, false negative, or 
    ambiguous results          
f. Genetic tests for inherited cancer      
   susceptibility are usually 
   covered by your patients’ medical 
   aid plans                                
g. It is difficult to ensure that patients’      
    test results will remain confidential                             
h. Patients with positive test results                 
    are at risk for insurance 
    discrimination   
i. Patients should not undergo                               
   genetic testing unless they get  
   genetic counseling about the risks, 
   benefits and consequences of the test.                                             
 
4. How qualified or unqualified do you consider yourself to recommend genetic testing for    
    inherited cancer susceptibility to your patients? (CHECK ONE BOX) 
   Very well qualified          Somewhat qualified       Not very well qualified 
      Not qualified at all           Don’t know 
 
5. How interested would you be in receiving continuing medical education credits for training in  
    genetic risk assessment and testing for inherited cancer susceptibility? (CHECK ONE BOX) 
    Very interested               Somewhat interested            Not very interested 
    Not interested at all        Don’t know 
 
6. In your opinion, is there a need for general practitioner guidelines for genetic testing for  
    inherited cancer susceptibility? 
       Yes                       No                    Don’t know 
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Thank you very much for your participation in this survey.   
 
If you would like to receive a summary report of the findings from this survey? Please remember to 
complete and return the postal card provided. 
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